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FANCONI ANEMIA (FA) is a rare inherited disorder that was first reported in 1927 by the 
Swiss pediatrician Guido Fanconi. He described a familial form of aplastic anemia (bone 
marrow failure) in three brothers with short stature, hypogonadism and abnormal skin 
pigmentation (Fanconi, 1927).  
The inheritance pattern of FA has traditionally been classified as autosomal recessive. 
However, the discovery of an FA gene on the X chromosome (FANCB) implicated an X-linked 
mode of inheritance in this disorder as well (Meetei et al., 2004).   
 
 
 
1. PREVALENCE 
 
FA is a rare disorder with a worldwide prevalence of around 3 per million and an estimated 
heterozygote (carrier) frequency of one in 300 in Europe and the United States (Swift, 1971; 
Schroeder et al., 1976). However, in some isolated populations, such as the Ashkenazi Jews, 
South African Afrikaners and Spanish gypsies, the carrier frequency for FA is higher, due to 
common founder mutations (Whitney et al., 1993; Tipping et al., 2001; Callén et al., 2005). 
Since the first report in 1927 by Dr. Fanconi, over 1300 FA patients have been diagnosed 
worldwide and collected in the International Fanconi Anemia Registry (IFAR)*1 (Alter, 2003). 
 
 
 
2. CLINICAL ASPECTS 
 
The main clinical manifestation of FA is related to the hematological abnormalities that become 
apparent early in life. FA is therefore classified as a bone marrow failure syndrome in children. 
In fact, at the median age of 7 years, children with FA frequently develop aplastic anemia (also 
called pancytopenia) resulting in a malfunction or suppression of multipotent myeloid stem 
cells. This hematopoietic deficit is associated with inadequate production or release of the 
differentiated cell lines, such as blood cells, platelets (thrombocytopenia) and leukocytes 
(neutropenia) (Tischkowitz & Hodgson, 2003) or loss of the stem cells.   
In addition to ineffective hematopoiesis, FA patients have a high risk of developing acute 
myeloid leukemia (AML) and myelodysplasia syndrome (MDS). The risk of developing AML 
was evaluated to be 15 000-fold higher in FA patients compared to age-matched normal 
individuals (Auerbach & Allen, 1991). Bone marrow samples of FA patients with AML/MDS 
frequently show cytogenetic aberrations, such as trisomy 1q, monosomy 5 and monosomy 7. 
Furthermore, gain of chromosome 3q with monosomy 7 is strongly associated with an increased 
risk of developing AML/MDS and represents an important marker of poor prognosis (Tonnies 
et al., 2003).  
FA patients may also develop non-hematological features, which are highly heterogeneous 
and vary among patients, even within the same family. Nevertheless, a typical FA patient 
exhibits physical abnormalities, such as short stature (growth retardation), abnormal thumbs and 
radius, microcephaly, and skin pigmentation problems (café-au-lait spots). The variety and 
frequency of congenital malformations seen in FA patients are summarized in Table 1. 
Importantly, up to thirty per cent of the patients do not show any obvious congenital 
abnormality, which makes it difficult to diagnose FA solely based on the clinical phenotype.  
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TABLE 1. Frequency of abnormalities in Fanconi anemia*  
Abnormality                                                                                                   Frequency (%) 
Skeletal (radial ray, hip, scoliosis, rib)               71 
Skin pigmentation (café-au-lait spots, hyper-hypopigmentation)         64 
Short stature               63 
Eyes (microphtalmia)              38 
Renal and urinary tract              34 
Male genital               20 
Mental retardation              16 
Gastrointestinal (e.g. anorectal, duodenal atresia)     14 
Cardiac                13 
Hearing                11 
Central nervous system (e.g. hydrocephalus, septum pellucidum)       8 
No congenital abnormalities             30 
                                                                                                                                   * From Tischkowitz & Dokal, 2004 
 
 
While AML is the most common malignancy in FA, patients that reach early adulthood are 
~50 times more likely to develop solid tumors compared to the general population. These 
patients have a very high risk for developing squamous cell carcinomas particularly in the head 
and neck and anogenital region (Alter, 2003; Rosenberg et al., 2003). It has been shown that the 
human papillomavirus might play a role in the pathogenesis of these tumors (Kutler et al., 
2003), although this is still a matter of debate (van Zeeburg et al., 2004). Moreover, high risk of 
hepatic tumors is also frequently observed in FA patients treated with androgens for bone 
marrow failure (Young & Alter, 1994).  
The clinical phenotypes of FA patients depend on many factors, such as ethnic and individual 
genetic background, environmental factors or a particular type of mutation (Gillio et al., 1997; 
Futaki et al., 2000). The variety of malformations observed in FA patients suggests that the 
associated FA genes are involved in the normal development of various organ systems. 
 
 
 
3. CELLULAR ASPECTS 
 
3.1. Genome instability and hypersensitivity to DNA cross-linking agents 
 
Cells from FA patients show spontaneous chromosomal instability. Analyzed by classical 
cytogenetic methods, metaphases from FA lymphocytes exhibit spontaneous chromosomal 
aberrations, including chromatid breaks and quadriradial chromosomes (Schroeder, et al., 
1964). In addition, both primary and immortalized FA lymphocytes are extremely sensitive to 
antimitotic agents that induce interstrand cross-links (ICLs) in DNA (also called bifunctional 
alkylating agents), such as mitomycin C (MMC), diepoxybutane (DEB), cisplatin, 
photoactivated psoralens and derivatives of nitrogen mustard (Sasaki & Tonomura, 1973; Ishida 
& Buchwald, 1982). In response to these agents, the FA metaphases show an increased number 
of chromosome damages compared to metaphases of normal lymphocytes (Figure 1). The 
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cross-linking agents produce a covalent link between both strands of the DNA double helix, 
which prevent their separation, and block DNA and RNA polymerases. Since this block occurs 
during DNA replication or transcription, ICLs are extremely cytotoxic, mainly for proliferating 
cells. 
 
 
 
 
Figure 1. FA cells treated with cross-linking agent (e.g. MMC) and harvested in metaphase*. The 
arrows show typical chromosomal aberrations found in FA cells, such as chromatid breaks and 
interchanges. 
 
 
Because of the heterogeneous clinical phenotype of FA patients, it is often difficult to 
formulate a firm diagnosis solely on that basis. The cellular hypersensitivity to DNA cross-link 
agents is, therefore, the most consistent phenotype and provides a useful criterion for both pre- 
and postnatal diagnosis (Cervenka et al., 1981).  
The standard MMC/DEB chromosome breakage test on blood lymphocytes could give 
“falsely negative” diagnosis in some patients with somatic mosaicism (mixture of normal 
reverted and affected lymphocyte populations). The corrected cellular phenotype (reverse 
mosaicism) may be attributed to various mechanisms, such as gene conversion, back mutations 
or compensatory deletions/insertions. Importantly, this phenotype may confer a proliferative 
advantage to the reverted lymphoid cells (Lo Ten Foe et al., 1997; Waisfisz et al., 1999b; Gross 
et al., 2002, Mankad et al., 2006). In order to provide a more accurate FA diagnosis in case of 
mosaicism, the chromosome breakage test must be performed on skin fibroblasts (Joenje et al., 
1998). 
  
Based on the observed chromosome breakage and DNA cross-linker hypersensitivity, FA is 
classified among the caretaker gene disorders together with a number of rare inherited 
chromosomal instability syndromes that are all associated with cancer susceptibility (see Table 
2). Studies on these disorders have provided important insights into how disruption of distinct 
DNA repair mechanisms can lead to genomic instability, and consequently, predispose patients 
to cancer development. The chromosomal instability syndromes presented in Table 2 can be 
14     Chapter 1    
inherited in either a dominant or a recessive mode. In the dominant mode of inheritance, the 
affected individual inherits only one mutant allele of a given gene (e.g. BRCA1/2 genes for the 
hereditary breast cancer and DNA mismatch repair genes for the hereditary non-polyposis 
colorectal cancer). In that case, the patient is heterozygous and the carcinogenesis process might 
be initiated by somatic inactivation of the other allele or by the haplotype insufficiency due to 
the presence of one mutant allele (Buchholz et al., 2002). In the recessive mode, each parent 
passes on one copy of an abnormal gene. This implies that both alleles of the affected individual 
have inherited mutations in a particular DNA repair gene (biallelic mutations).  
Cancer development is a consequence of the alterations of three types of genes: oncogenes, 
tumor suppressor genes and DNA repair genes (Vogelstein & Kinzler, 2004). Oncogenes 
contribute to cancer by a single mutational activation, whereas the tumor suppressor genes and 
DNA repair genes contribute to the cancer process when they are inactivated. Genes involved in 
DNA repair prevent carcinogenesis by protecting the genome against alterations that activate 
oncogenes or inactivate tumor suppressor genes. Therefore, germline mutations in both alleles 
of DNA repair genes lead to genomic instability and are associated with a number of cancer-
prone syndromes. For instance, Xeroderma pigmentosum (XP) patients have a defect in 
excision and repair of UV photoproducts in DNA and have a dramatically increased risk to 
develop skin cancer. The molecular DNA repair process affected in these genetic instability (or 
chromosomal fragility) syndromes are shown in Table 2. 
 
The exact DNA repair pathway that is defective in FA patients is still unknown. In fact, the 
molecular genetics of FA proteins seems to define a previously unknown multi-protein complex 
that is involved in the response to DNA cross-linking agents. Although the exact role of the FA 
proteins in ICL repair is still not completely resolved, recent findings have provided new 
insights into the role of FA in DNA repair during replication. For example, the finding that 
BRCA2 protein corresponds to FANCD1, and that FANCJ and FANCM contain enzymatic 
domains that are involved in DNA processing, directly implicates FA in DNA repair through 
homologous recombination (HR) and translesion synthesis (TLS) (see, Tables 2 and 4) (Howlett 
et al., 2002; Levitus et al., 2005; Levran et al., 2005; Meetei et al., 2005). The role of these 
mechanisms in the FA pathway will be discussed in Chapter 6. 
 
Most of the proteins involved in cellular DNA damage response pathways converge in a 
common “tumor suppression network of interactions” that contribute to genome stability of the 
human cells (Surrallés et al., 2004). FA proteins interact (functionally and/or physically) with 
several other DNA repair proteins or pathways that are involved in genetic instability 
syndromes or DNA damage responses (Rosselli et al., 2003; Macé et al., 2004). These proteins 
include ATM, ATR, BLM, BRCA1, BRCA2, Rad50/MRE11/NBS1 complex, RAD51, RPA 
and XPF (Garcia-Higuera, et al., 2001; Digweed et al., 2002; Godthelp et al., 2002, 2005; 
Nakanishi et al., 2002; Pichierri et al., 2002, 2004; Tanuguchi et al., 2002a, 2002b; Meetei et 
al., 2003a; Sridharan et al., 2003; Wong et al., 2003; Andreassen et al., 2004; Wang et al., 2004; 
Howlett et al., 2005). The molecular cross-talk between the FA proteins and the other DNA 
repair proteins suggests that the FA proteins play a central role in the interactions within this 
network. Indeed, the phenotypic overlap between some FA, NBS, and BLM patients may 
indicate a tight molecular cross-talk between the proteins involved in these syndromes.  
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       TABLE 2. Genetic instability syndromes associated to cancer predisposition* 
aAutosomal dominant inherited disorders            *Modified from Rosseli et al., 2003 
bSee Hayani et al., 1994; Alderton et al., 2004                        *Abbreviations 
 
 
 
In addition to the typical cross-link repair defect observed in FA cells, studies over the past 
years have indicated several other cellular phenotypic features. This implies that the FA 
pathway participates in a complex network that is essential to maintain genetic integrity. Some 
of these aspects are briefly discussed below. 
 
Syndrome Affected gene(s) 
Defective DNA        
repair process 
Principal 
cancer 
predisposition 
Ataxia    
telangiectasia 
(AT) 
ATM 
 DSB
* response Leukemia, lymphoma 
Bloom 
syndrome 
(BLM) 
BLM HR
*/ DNA 
unwinding 
All 
malignancies 
occurring in the 
normal 
population 
Fanconi anemia   
(FA) 
FANCA, -B, -C, 
-D1/BRCA2, -D2, 
-E, -F, -G, -I, 
-J/BRIP1, -L, -M 
HR*? 
TLS*? 
Acute myeloid 
leukemia & 
Squamous cell 
carcinoma 
Hereditary 
breast cancera BRCA1, BRCA2 HR
* Breast/ovarian cancers 
Hereditary non-
polyposis 
colorectal 
cancera    
(HNPCC) 
MSH1, MSH2 
MLH6, 
PMS1, PMS2 
MMR* Colorectal cancer 
Nijmegen 
breakage 
syndrome 
(NBS) 
NBS1 DSB* response Leukemia, lymphoma 
Seckel 
syndrome 
(SCKLS)b 
ATR replication fork stalling 
Leukemia, 
lymphoma 
Werner    
syndrome gland 
(WRN) 
WRN HR*/replication 
Osteosarcoma 
&  carcinoma of 
thyroid 
Xeroderma 
pigmentosum 
(XP) 
XPA, -B, -C,  -D, 
-E, -F, -G NER
*/TCR* Skin cancers 
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3.2. Cell cycle abnormalities  
 
Another important cellular characteristic in FA cells is the impairment of the cell cycle. This 
impairment occurs either spontaneously or after introduction of ICL. FA cells spontaneously 
arrest in late S or delay at G2/M transition of the cell cycle compared to wild-type cells 
(Dutrillaux et al., 1982), a phenomenon that is further exaggerated when cells are treated with 
DNA cross-linking agents (Heinrich et al., 1998). In normal cells, ICL treatment during the G2 
phase of the cell cycle does not induce a G1 or G2/M arrest, but requires DNA replication to 
provoke growth arrest (Akkari et al., 2000). Similar to wild-type cells, the ICL-induced 
chromosome breakage seen in FA cells occurs only after DNA replication and only if cells fail 
to arrest (Centurion et al., 2000; Sala-Trepat et al., 2000; Akkari et al., 2001). Importantly, FA 
cells are not completely inefficient in repairing cross-linked DNA but are ~3 times slower than 
wild-type cells, indicating that FA has a primary defect in ICL repair during late S phase 
(Akkari et al., 2001). In other words, the ICLs seem to be tolerated in the double-strand DNA 
until they are hit by a replication fork. 
 
 
3.3. Oxygen sensitivity 
 
Some studies showed that primary FA skin fibroblast cultures grow better in low oxygen 
(Schrindler & Hoehn, 1988) and that FA lymphocytes exhibit elevated chromosomal 
aberrations under higher oxygen concentrations (Joenje et al., 1981). These findings suggest 
that FA proteins are involved in the defense against oxygen toxicity and in the repair of 
oxidative damages (for review, see Pagano & Youssoufian, 2003). In line with this, some FA 
proteins have been related to the regulation of oxygen metabolism. The FANCC protein, for 
example, interacts both physically and functionally with a number of cytoplasmic proteins 
known to catalyse the production of reactive oxygen species, such as the nicotin-amide adenine 
dinucleotide phosphate (NADPH) cytochrome P450 reductase (Kruyt et al., 1998) and the 
glutathione S-transferase P1 (GSTP1) (Cumming et al., 2001). Similarly, the FANCG protein 
interacts directly with protein P450 cytochrome 2E1 (CYP2E1) and down-regulates the level of 
CYP2E1 (Futaki et al., 2002). These interactions suggest that some FA proteins play a role in 
detoxifying metabolism. 
A recent study proposed that oxidative stress facilitates the FANCA-FANCG interaction and 
also induces multimerization of the FA proteins (FANCA, FANCC and FANCG) through 
intermolecular disulfide linkage(s) (Park et al., 2004). However, further studies are required to 
establish whether the FANCA-FANCG interaction via disulfide linkage(s) is essential for the 
normal function of FA proteins in response to DNA damage.  
Since the DNA cross-link agents (e.g. MMC and DEB) produce reactive oxygen species, it 
has been proposed that the sensitivity of FA cells to those agents may be due to the incapacity 
to neutralize reactive oxygen species (Korkina et al., 2000). However, FA fibroblasts 
transformed with SV40 large T-antigen lack hypersensitivity to oxygen but maintain 
hypersensitivity to MMC (Saito et al., 1993), which suggests that the oxygen sensitive 
phenotype is a secondary defect in FA cells.    
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3.4. Apoptosis and telomere maintenance 
 
The regulation of apoptotic mechanisms (programmed cell death) seems to be disrupted in FA 
cells. For example, the level of apoptotic cells that occur spontaneously or induced by MMC is 
significantly increased in FA cells (Kruyt et al., 1996; Ridet et al., 1997). The high level of 
apoptosis in bone marrow stem cells and during embryogenesis may account for the depletion 
of hematopoietic reserves and developmental abnormalities commonly seen in FA patients (for 
review, see Rosselli, 1998).  
One of the FA proteins, FANCC, seems to be involved in the regulation of apoptosis in 
hematopoietic cells, since it protects the progenitor cells from the fas-mediated apoptotic 
pathway (Wang et al., 1998). FANCC also prevents apoptosis by augmenting the activity of the 
GSTP1 protein (Cumming et al., 2001). In addition, the GSTM1 genotype significantly 
influences the progression of bone marrow failure in FA complementation group C patients 
(median age 3 years vs 7 years) by increasing susceptibility to cytokine-induced apoptosis 
(Davies et al., 2005). 
Telomeres protect the ends of the chromosomes by preventing fusion (Blasco et al., 1999). 
Therefore, telomeres have an important role in genomic stability, and more precisely, in 
adequate functioning of the hematopoietic system (Herrera et al., 1999). A study by Callén and 
colleagues (2002) on FA cells showed a higher rate of breakage at telomeric sequences and in 
chromosome end fusion (>10-fold), which indicates a defect in telomere maintenance (see also 
Li et al., 2003). This effect also occurs in similar hematopoietic syndromes, such as in acquired 
aplastic anemia, in MDS and in AT (a syndrome caused by mutations in the ATM gene, see 
Table 2) (Metcalfe et al., 1996; Boultwood et al., 1997; Brummendorf et al., 2001). A defect in 
telomere maintenance may therefore contribute to the genomic instability of FA cells. 
 
 
 
4. FA GENES AND PROTEINS  
 
4.1. Genetic heterogeneity 
 
The genetic heterogeneity in FA patients was traditionally assessed by complementation 
analysis through somatic cell fusion experiments. These experiments use the characteristic 
sensitivity of FA cells to DNA cross-linking agents such as MMC/DEB (Duckworth-Rysiecki  
& Taylor, 1985; Buchwald, 1995; Joenje et al., 1995, 1997). Briefly, if the fusion of two 
immortalized FA lymphoblastoid cell lines results in a MMC-resistant hybrid cell, the two 
patients have different defective FA genes, and therefore belong to different complementation 
groups. Otherwise, if the fusion results in a MMC-sensitive hybrid cell, the two patients have 
the same defective FA gene, and are therefore considered to belong to the same 
complementation group (Figure 2). This method, however, may result in mis-assignments due 
to phenotypic reversion or chromosome loss. Therefore, very stringent criteria have to be 
applied. Joenje and colleagues proposed that before declaring a new FA complementation 
group, at least two patient cell lines have to be excluded from all known subtypes and show to 
belong to the same group by cell fusion experiments (Joenje et al., 2000). Gene 
complementation or identification of pathogenic mutations in the associated FA gene provides 
definitive proof that a patient cell line belongs to the assigned complementation group.  
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4.2. FA complementation groups 
 
To date, twelve FA complementation groups have been established: FA-A, -B, -C, -D1, -D2, -E, 
-F, -G, -I, -J, -L and -M, where each subtype represents a distinct FA gene. Complementation 
group A is the most common FA subtype, accounting for ~65% of the patients. The FA-C and 
FA-G groups represent less than 10% of the cases and the other subtypes are very rare (Table 3) 
(Levitus et al., 2004). 
 
 
TABLE 3. FA complementation groups distribution (in %)* 
A 64 F 2 
B 2 G 8 
C 9 I 2 
D1 3 J 3 
D2 3 L <1 
E 3 M <1 
*Results are based on the first 245 (updated to 251) FA families classified   
by the European Fanconi Anemia Research Program (1994-2003).  
Figure 2. FA complementation 
analysis through somatic cell fusion 
experiments. The hybrid cell is 
subjected to a MMC test and the 
resulting phenotype determines 
whether the different FA cell lines 
belong to the same or different 
complementation group(s). 
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There is some correlation between specific complementation groups, type of mutations and 
clinical features in FA. The FA-C patients with the IVS4+4A®T and L554P mutations are 
associated with early onset of hematological abnormalities and multiple birth defects, while 
individuals with the 322delG and Q13X mutations have milder clinical outcome with a reduced 
incidence of somatic abnormalities (Gillio et al., 1997; Faivre et al., 2000). Nevertheless, 
additional factors appear to influence the clinical phenotype, since the FANCC IVS4+4A®T 
mutation results in milder phenotype in Japanese patients (Futaki et al., 2000). In a genotype-
phenotype study of 245 FA patients, Faivre and colleagues reported that the rare FA subtypes 
D, E and F have a higher incidence of somatic abnormalities (Faivre et al., 2000). In general, 
the patients from complementation group D1 have a more severe clinical phenotype compared 
to the other subtypes. The FA-D1 patients, who carry biallelic mutations in the BRCA2 gene, 
are associated with earlier onset of acute myeloid leukemias and solid tumors, such as Wilm’s 
tumors and medulloblastomas (Offit et al., 2003; Hirsch et al., 2004; Wagner et al., 2004). 
Patients from complementation group E exhibit malformations of the central nervous system 
(Faivre et al., 2000). These malformations appear to be represented mostly in FA-E patients 
(60% of cases), compared to the other FA patients (<4%). The patients with FANCG mutations 
and FANCA null mutations seem to represent a high-risk group with a poor hematologic 
outcome. In support of this, FA-A cells with FANCA null mutations have a MMC sensitivity 
severely impaired while FANCA mutations producing abnormal FANCA proteins complement 
the MMC sensitivity to different extends (Adachi et al., 2002). Therefore, the complete loss of 
FANCA function versus partial FANCA function might reflect the phenotypic variation seen in 
FA-A patients.   
 
 
4.3. Gene identification 
 
A number of methods were used to identify FA genes, such as expression cloning, positional 
cloning, direct sequencing of candidate genes and protein complex purification. Currently, 
eleven of the twelve FA genes have been identified, as the FANCI gene remains to be cloned 
(Levitus et al., 2004). The principal features of the FA genes and related proteins are 
summarized in Table 4. 
 
Many of the FA genes were identified using functional complementation of the cross-linker 
sensitive phenotype of FA cells with wild-type cDNAs. This technique uses a cDNA expression 
library cloned in an episomal mammalian expression vector (pREP4) that is transfected into a 
lymphoblastoid cell line derived from an FA patient (Strathdee et al., 1992). The transfected 
cell line is first selected for vector uptake using hygromycin and then subjected to MMC to 
select the cells that have corrected the FA phenotype. Thus, the cell line that becomes resistant 
to DNA cross-linking agents is complemented (corrected) by the cDNA that encodes the protein 
affected by the defective FA gene. The vector DNA is isolated from the complemented pool of 
cells and the cDNA insert analyzed. To further confirm that the candidate cDNA is indeed 
representing an FA gene, mutation screening in the corresponding FA patient cell lines should 
reveal pathogenic sequence alterations. This cloning strategy has, however, some limitations, 
since the overexpressed cDNA might be toxic for the cells or the cDNA library might not 
contain a specific FA cDNA. In addition, false positive cDNA might by found when a cell line 
becomes MMC resistant due to phenotypic reversion. 
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TABLE 4. FA complementation groups and FA genes 
Subtype     FA gene         Chromosomal          Molecular                 Cellular                  Motifs/Domains  
                                               location               weight (kDa)           localization                  or Function 
A FANCA            16q24.3            163        N/C                  bipartite NLS,                       
                                                          leucine zipper 
B FANCB            Xp22.3                       95            N/C   NLS 
C               FANCC            9q22.3                          63             N/C                                - 
D1             FANCD1/           13q12.3             38                          N                          8 BRC repeats, 
                   BRCA2   RAD51 recruitment  
D2             FANCD2             3p26            155-162                   N               K561 monoubiquitinated, 
        S222 phosphorylated 
E               FANCE a              6p21.3             60                          N                          2 NLS 
F               FANCF            11p15                42             N                  adaptor protein 
G              FANCG           9p13                  68                   N/C                   leucine zipper, 
        7 TPR motifs 
I                FANCI b                    ?                                ?                          ?                            ? 
J                FANCJ/           17q22             150                        N          5’® 3’DNA helicase, 
                  BRIP1                                                         BRCA1binding                                                         
L               FANCL                 2p16             43                      N/C                WD40 repeats, 
RING finger 
E3 ubiquitin ligase 
M              FANCM                14q21.2             250                        N                    DNA translocase, 
                                  helicase domain            
adescribed in this thesis, Chapters 2 and 3      N = nuclear; C= cytoplasmic 
bnot identified         NLS = nuclear localization signal 
 
 
 
 
Another important method to identify new FA genes is through protein complex purification. 
These experiments in HeLa nuclear extract allowed the immunoisolation of a protein complex 
(BRAFT) that is associated with BLM, the helicase involved in Bloom syndrome (see Table 2). 
This protein complex contains BLM, replication protein A (RPA), FANCA and Topoisomerase 
IIIa (Topo IIIa) (Meetei et al., 2003a). The purification of BRAFT with FANCA antibody led 
to the isolation of five FA core complex proteins (FANCA, C, E, F and G), as well as several 
unidentified FANCA-associated polypeptides (FAAPs) or BLM-associated polypeptides 
(BLAPs). These polypeptides are termed FAAP or BLAP followed by a number that 
corresponds to their molecular weight. Some of these polypeptides, FAAP43, FAAP95 and 
FAAP250, were later classified as FA proteins by western blot and mutation analyses in FA 
patients, and represent FANCL, FANCB and FANCM, respectively (Meetei et al., 2003b, 2004, 
2005).  
Presently, two FA related polypeptides of this immunopurified BRAFT complex (i.e. 
FAAP75/BLAP75 and FAAP100) remain to be characterized.  FAAP75 seems not to be 
involved in the FA pathway but functions together with Bloom’s helicase to preserve genomic 
stability (Yin et al., 2005). Furthermore, the FAAP100 protein cannot represent the FANCI 
gene product since a normal protein level was found in FA-I cells (Medhurst et al., unpublished 
results).   
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4.4. Description of the FA genes and proteins 
 
In this section, the main characteristics of the currently known FA genes and proteins will be 
presented in order of identification. A comprehensive model for the FA protein-protein 
interactions inside a common pathway will be proposed in Chapter 6 (General Discussion). The 
hypothetical function of the FA pathway in the DNA cross-link repair process will also be 
discussed in Chapter 6.  
 
 
FANCC  
 
FANCC is the first identified FA gene and it was isolated by cDNA expression cloning in 1992 
(Strathdee et al., 1992). The FANCC cDNA encodes a protein of 558 amino acids with an 
estimated molecular weight of 63 kDa. The gene maps to chromosome 9q22.3 and consists of 
14 exons. Diverse forms of FANCC mRNAs were detected, which indicates that the regulation 
of this gene might be complex. The role of these FANCC transcripts is still unknown (Gibson et 
al., 1993; Savoia et al, 1995). 
The first studies on the intracellular localization of FANCC revealed that FANCC is localized 
to the cytoplasm (Yamashita et al., 1994; Youssoufian, 1996). Later, subcellular fractionation 
experiments and confocal microscopy analyses showed that FANCC is present in both 
compartments of the cells, with a weak trace of FANCC (about 10%) in the nucleus (Hoatlin et 
al., 1998). The expression of FANCC is regulated during cell cycle progression with the lowest 
levels at the G1/S boundary and maximal levels at the G2/M transition (Kupfer et al., 1997a; 
Heinrich et al., 2000). This cell cycle regulation appears to be subject of posttranslational 
mechanisms that use proteasome-dependent proteolysis (Heinrich et al., 2000).   
The FANCC protein interacts with and regulates the function of various non-FA proteins, in 
the cytoplasm as well as in the nucleus of the cell. The cytosolic partners of FANCC include the 
mitotic cyclin-dependent kinase cdc2 (regulator of the transition from G2 to M phase), the 
stress response proteins and molecular chaperones GRP94 and Hsp70, proteins involved in 
oxygen radical metabolism (i.e. the NADPH cytochrome P450 reductase and GSTP1), and the 
signal transducer and activator of transcription, STAT1 (Kupfer et al., 1997a, Kruyt et al., 1998; 
Hoshino et al., 1998; Pang et al., 2000, 2002; Cumming et al., 2001). In the nucleus, FANCC 
interacts with a member of the BTB/POZ family of transcriptional repressor proteins, FAZF 
(Hoatlin et al., 1999).  
The interaction of FANCC with non-FA proteins suggests that FANCC, in addition to its role 
in cross-link repair (as discussed earlier), is involved in cell cycle control, protein transport, 
anti-apoptotic pathway, detoxification mechanism and signal transduction (Bogliolo et al., 
2002). Consistent with this multifunctional role, structurally separate functional domains 
implicated in the nuclear damage process and cytoplasmic actions of the cell were found in the 
FANCC protein (Pang et al., 2001). 
 
 
FANCA  
 
The FANCA gene, which is defective in most FA patients (Table 3), was mapped to 
chromosome band 16q24.3 (Pronk et al., 1995) and identified simultaneously by expression 
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cloning and positional cloning strategies in 1996 (FA/Breast Cancer Consortium, 1996; Lo Ten 
Foe et al., 1996). FANCA contains 43 exons resulting in a mRNA transcript of 5.5-kb that 
encodes a protein of 1455 amino acids with a predicted molecular weight of ~163 kD. The 
primary amino acid sequence of FANCA reveals two overlapping bipartite nuclear localization 
signals (NLS) at its N-terminus (a.a 18-34 and 19-35) and a leucine-zipper motif between 
residues 1069 and 1090.  
FANCA is present in both the cytoplasm and nucleus of the cell, but is predominantly 
localized in the nuclear compartment  (Kupfer et al., 1997b). The nuclear accumulation of 
FANCA requires the bipartite NLS motifs, as well as the C-terminal region (Näf et al., 1998; 
Lightfoot et al., 1999; Kupfer et al., 1999). Moreover, the nuclear accumulation and function of 
FANCA seem to depend on its phosphorylation by an unknown cytoplasmic serine kinase 
(Yamashita et al., 1998; Yagasaki et al., 2001; Adachi et al., 2002). It is hypothesized that this 
phosphorylation event is stimulated by the FA core complex proteins (i.e. FANCB, FANCE, 
FANCF and FANCG), since it is lacking in FA cells of complementation groups B, E, F and G, 
but present in FA-D1 and -D2 cell lines (Yamashita et al., 1998; Kupfer et al., 1999). The 
nuclear accumulation of FANCA also depends on FANCB, -L and -M (de Winter et al., 2000b; 
Meetei et al., 2003b, 2005). Furthermore, FANCA contains nuclear export signals that seem to 
play a role in the nuclear accumulation of FANCA (Ferrer et al., 2005).  
 
 
FANCG/XRCC9  
 
In 1998, de Winter and colleagues identified the FA complementation group G gene. The 
FANCG gene appeared to be identical to the human XRCC9 gene, isolated on the basis of its 
capacity to complement the Chinese hamster ovary (CHO) mutant UV40 (Liu et al., 1997). This 
gene is located at chromosome band 9p13 and contains 14 exons that encode a protein of 622 
amino acids (molecular weight  ~70 kDa). 
The FANCG protein localizes to the cytoplasm and nucleus of the cell and interacts directly 
with FANCA (Waisfisz et al., 1999a). Studies on the structure/function of FANCA and FANCG 
revealed that amino acids 1-428 of FANCG bind to the N-terminal NLS of the FANCA protein 
(Näf et al., 1998; Kuang et al., 2000). Additional functional analyses of patient-derived FANCG 
mutations also showed that FANCG has a C-terminal functional domain, which appears to be 
required for normal assembly of the FANCA/FANCC/FANCG protein complex (Kuang et al., 
2000; Nakanishi et al., 2001).  
Comparative amino acid sequence analysis of the zebrafish Fancg ortholog and human 
FANCG reveals seven tetratricopeptide repeat motifs (TPRs) in FANCG (Blom et al., 2002, 
2004). TPRs are degenerate 34 amino acid repeat motifs that form a scaffold structure for 
protein-protein interactions, which suggests that FANCG is essential in the assembly and/or 
stability of the FA core complex. Four of the TPRs in FANCG are required for binding FANCA 
and are of functional importance. 
FANCG is subjected to posttranslational modification, such as phosphorylation (Futaki et al., 
2001). The phosphorylation sites in FANCG were mapped to serines 7, 383 and 387 (Qiao et 
al., 2004; Mi et al., 2004). During the cell cycle (at mitosis), the FA proteins detach from 
chromatin and FANCG becomes phosphorylated at serines 383 and 387 (Qiao et al., 2001, 
2004). The G2/M kinase cdc2, which binds to FANCC, appears to phosphorylate FANCG-
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Ser387 (Kupfer et al., 1997a; Mi et al., 2004). However, the function of these phosphorylation 
steps and the overall consequences on the FA pathway remain to be clarified. 
 
  
FANCF  
 
FANCF, the gene mutated in complementation group F, was identified in 2000 by expression 
cloning. This gene consists of one single exon and its cDNA of ~1.3 kb is translated into a 
protein of 374 amino acids (molecular weight of 42 kDa) (de Winter et al., 2000a). FANCF 
maps to chromosome 11p15 (de Winter et al., 2000a) in a hot-spot area for hypermethylation, 
indicating that the mRNA levels of FANCF partly depend on methylation (Taniguchi et al., 
2003). 
To date, 5 FA-F patients have been identified worldwide and the mutational analysis*2 of 
those patients did not reveal any missense mutation that could point out functional domains in 
FANCF (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The FANCF protein is predominantly localized in the nucleus of the cell, where it is able to 
form a complex with FANCA, FANCC and FANCG (de Winter et al., 2000b). The C-terminal 
region of FANCF is directly involved in the interaction with FANCG (Medhurst et al., 2001; 
Gordon & Buchwald, 2003). Furthermore, FANCF is present in FA cells derived from 
complementation groups A, B, C, D1, D2, E and G, and appears to stabilize the FANCA, 
FANCC, FANCG proteins in the complex (Siddique et al., 2001). In Chapter 5, I will present a 
site-directed mutagenesis study on the FANCF protein. This study reveals important findings on 
functional domains and residues in FANCF and provides new insights into the role of FANCF 
in the FA pathway.  
 
 
FANCE  
 
FANCE is the fifth and until now, last FA gene that has been cloned by the expression cloning 
method (Chapter 2). The FANCE protein directly binds both FANCC and FANCD2 (Medhurst 
et al., 2001; Pace et al., 2002). Moreover, FANCE is required for the nuclear accumulation of 
FANCC and links the FA core complex to the downstream FANCD2 protein (see below) 
TABLE 5. Individuals with FANCF mutations* 
Patient                          Mutation      Consequence for protein 
BD497                        484-485dela            deletion 
EUFA121                   349-395del            deletion 
         16C®T                Gln6STOP 
EUFA698                   230-252dela             deletion 
EUFA927                    327C®Ga             Tyr109STOP 
EUFA1228                 887-894dela            deletion 
aHomozygous mutation 
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(Taniguchi & D’Andrea, 2002; Pace et al., 2002). Further studies on the FANCE protein are 
presented in Chapter 4.  
 
 
FANCD2  
 
A gene defective in FA-D cells was localized to chromosome 3 at the locus 3p22-26, using 
microcell-mediated chromosome transfer and positional cloning approaches (Whitney et al., 
1995). The identification of the FA gene at this locus showed that the FA-D group is 
heterogenous and represents 2 FA genes: FANCD1 and FANCD2 (Timmers et al., 2001), the 
latter being the gene at 3p22-26.  
FANCD2 contains 44 exons and encodes a 1451 amino acids nuclear protein. Normal human 
cells express the FANCD2 protein in two isoforms: FANCD2-S (short) of 155 kDa and 
FANCD2-L (long) of 162 kDa. The long form is generated by the attachment of a single 
ubiquitin molecule to lysine residue 561 of the FANCD2 protein  (Timmers et al., 2001).  This 
monoubiquitination reaction is an essential step in the FA pathway and requires most of the FA 
core complex components (FANCA, -B, -C, -E, -F, -G, -L and -M). In this complex, FANCL 
seems to be the catalytic subunit of the monoubiquitination reaction (Meetei et al., 2004b). 
USP1 is the deubiquitinating enzyme that removes the ubiquitin moiety (Nijman et al., 2005). 
Monoubiquitinated FANCD2 assembles in nuclear foci that exist normally in the S phase of the 
cell cycle and after cellular exposure to DNA damaging agents that block DNA replication, 
such as MMC, ionizing radiation (IR) and deoxynucleotide depletion by hydroxyurea (HU) 
(Garcia-Higuera et al., 2001; Taniguchi et al., 2002b). This FANCD2 modification allows its re-
localization from a soluble nuclear compartment to the chromatin fraction and nuclear matrix 
(Meetei et al., 2004b), where it co-localizes in nuclear foci with numerous proteins involved in 
DNA repair and cell cycle checkpoint regulation, such as ATM, ATR, BLM, breast cancer 
proteins (BRCA1 and BRCA2), PCNA, RAD51 and the MRE11/RAD50/NBS1 (MRN) 
complex (Garcia-Higuera et al., 2001; Nakanishi et al., 2002; Pichierri et al., 2002, 2004; 
Taniguchi et al., 2002a, 2002b; Meetei et al., 2003a; Andreassen et al., 2004; Hussain et al., 
2004; Wang et al., 2004). 
FANCD2 appears to be involved in another pathway as well. In normal cells, when exposed 
to ionizing radiation, the ataxia telangiectasia kinase (ATM) phosphorylates FANCD2 on serine 
222 with the cooperation of the MRN complex (Nakanishi et al., 2002), which results in the 
activation of an S phase checkpoint response (Taniguchi et al., 2002b). In addition, ATR, an 
ATM- and RAD3-related protein kinase responsible for Seckel syndrome (see Table 2), also 
mediates the FANCD2 phosphorylation (Pichierri & Rosselli, 2004) and seems also involved in 
FANCD2 monoubiquitination (Andreassen et al., 2004).   
 
 
FANCD1/BRCA2  
 
The gene defective in FA complementation group D1 patients was found on the basis of a 
candidate gene approach. The BRCA1 and BRCA2 (breast cancer susceptibility gene 1 and 2) 
genes were good FA candidate genes since BRCA1 and BRCA2 deficient cell lines are 
hypersensitive to the interstrand cross-linking agent MMC (Patel et al., 1998; Moynahan et al., 
2001). Mutation screening of both genes was performed in cell lines derived from FA-B and 
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FA-D1 patients and biallelic BRCA2 mutations were detected in both cell lines (Howlett et al., 
2002). Functional complementation of the FA-D1 fibroblasts with wild-type BRCA2 cDNA 
restored the MMC hypersensitive phenotype, indicating that BRCA2 corresponds to FANCD1.  
Importantly, the FA-D1 cells express the monoubiquitinated form of FANCD2, suggesting 
that FANCD1/BRCA2 functions downstream of the FA core complex proteins (Garcia-Higuera 
et al., 2001). Recently, the FANCD2-L protein has been demonstrated to promote chromatin 
loading of FANCD1/BRCA2 (Wang et al., 2004). FANCD1/BRCA2 is a large nuclear protein 
of 3,418 amino acids that contains eight BRC repeat motifs, of which six bind the RAD51 
protein, and three oligonucleotide-binding domains that interact with single-stranded DNA 
(ssDNA) (Wong et al., 1997). The C-terminal portion of the FANCD1/BRCA2 protein is also 
involved in the binding of RAD51 and includes a nuclear localization signal. The RAD51 
protein functions as a helical polymer, composed of hundreds of monomers, that wraps around 
ssDNA and forms a nucleoprotein filament involved in homologous recombination (West, 
2003). In addition, FANCD1/BRCA2 drives RAD51 to sites of DNA damage (Davies et al., 
2001) and is required for stabilization of stalled DNA replication forks (Lomonosov et al., 
2003).  
Similar to FANCD2, FANCD1/BRCA2 is an ATM substrate and phosphorylation appears to 
activate the IR-inducible S phase checkpoint response (Wang et al., 2004). 
  
 
FANCL  
 
FANCL is the first FA gene that has been identified by biochemical approaches and the FANCL 
protein is the first FA protein with an enzymatic activity. Several FANCA associated proteins 
(FAAP43, FAAP95, FAAP100 and FAAP250) were discovered by immunoprecipitation with 
an FANCA specific antibody (Meetei et al., 2003a). FA complementation group L was 
identified by western blot analysis revealing the absence of FAAP43 in a single FA patient. 
This protein corresponds to PHF9 (PHD finger protein 9), a protein with three WD40 repeats 
and a RING-type zinc-finger motif that has E3-ubiquitin ligase activity (Meetei et al., 2003b). 
The FANCL protein is present in both nuclear and cytoplasmic compartments of the cell 
(Meetei et al., 2003b) and appears to play an important role in a catalytic reaction within the FA 
pathway. A recent study by Meetei and colleagues (2004) showed that FANCL is the ubiquitin 
ligase responsible for the FANCD2 monoubiquitination (FANCD2-L), but not BRCA1, as 
previously thought. Furthermore, they found that FANCL is necessary, but not sufficient for the 
monoubiquitination of FANCD2. Consequently, all the components of the FA core complex 
seem to act as a “regulated ubiquitin ligase” in which FANCL represents the catalytic subunit. 
In line with this, the WD40 repeat regions in FANCL appear to be required for its interaction 
with the FA core complex and the RING motif, for the recruitment of a putative E2 ubiquitin-
conjugating enzyme for monoubiquitination of FANCD2 (Gurtan et al., 2006).      
 
 
FANCB  
 
Similar to FANCL, the FANCB protein is one of the components of the purified FANCA 
complex (FAAP95). This polypeptide is mutated in FA patients belonging to complementation 
group B. The FANCB protein contains a bipartite nuclear localization signal at its C-terminus 
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(Meetei et al., 2004). Consistent with this finding, FANCB is predominantly detected in the 
nuclear extract of HeLa cells.  
The FANCB gene is located on the X chromosome at Xp22.31. In male individuals only one 
X chromosome is present and in females, the X chromosome is subject to X-inactivation. Thus, 
the FANCB gene is the only FA gene present in a single active copy in the human genome. 
Therefore, compared to the other autosomal FA genes, FANCB can be inactivated by a single 
mutation event, which could lead to genomic instability and cellular transformation. Since 
FANCB has a higher chance to be inactivated, it might be implicated in sporadic cancer in the 
general population (see below) and FA families belonging to complementation group B would 
necessitate clinical management (Rahman & Ashworth, 2004).  
 
 
FANCM  
 
Two separate research groups have found that the human ortholog of the archaebacterial protein 
HEF (Helicase-associated Endonuclease for Fork structured DNA) is a component of the FA 
core complex. The FANCA-associated polypeptide of 250 kDa (FAAP250) turned out to be 
closely related to Hef (Meetei et al., 2005). Immunoblotting of FAAP250 on several FA patient-
derived cell lines, revealed that the protein was present in cells of patients from the eleven 
known FA subtypes, but absent in cells from one FA patient who was excluded from many 
complementation groups (Meetei et al., 2005). Subsequent genotyping of this FA individual’s 
cDNA confirmed that FAAP250 is the gene defective in this patient, which established a new 
FA complementation group, FA-M (Meetei et al., 2005). A second research group found that 
the vertebrate Hef ortholog is an important component of the FA pathway by using knockout 
approaches in chicken DT40 cells (Mosedale et al., 2005). 
Like the other FA core complex proteins, FANCM is essential for the monoubiquitination of 
FANCD2. Furthermore, FANCM is a phosphoprotein that becomes hyperphosphorylated in 
response to DNA damaging agents. This posttranslational modification seems to occur 
independently of the other components of the FA core complex and may serve as a signal that 
regulates the ubiquitin ligase activity of the FA core complex (Meetei et al., 2005).     
The discovery of FANCM (and FANCJ, see below) provided a breakthrough in the 
understanding of the FA pathway and strongly linked FA to the DNA repair process. FANCM 
possesses two potential DNA-metabolizing domains: a DEAH-box helicase domain and an 
endonuclease domain homologous to ERCC4/XPF (an endonuclease essential for nucleotide 
excision repair, see Table 2). The helicase domain of FANCM has an ATPase activity, which is 
stimulated by single- and double-stranded DNA, whereas its endonuclease domain seems to be 
inactive. FANCM is able to dissociate triplex DNA, possibly reflecting its ability to translocate 
on duplex DNA (Meetei et al., 2005). 
 
 
FANCJ/BACH1/BRIP1  
 
Using homozygosity mapping and candidate gene screening approaches, recent studies revealed 
that BACH1 (BRCA1 Associated C-terminal Helicase) or BRIP1 (BRCA1-Interacting Protein 
C-terminal helicase) is the gene defective in the FA complementation group J (Levitus et al., 
2005; Levran et al., 2005; Litman et al., 2005). Moreover, the link between BRIP1 and the FA 
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pathway has been established by knockout experiments in chicken DT40 cells (Bridge et al., 
2005). 
 FANCJ/BRIP1 is a member of the RecQ DEAH-box helicase family, which efficiently 
unwinds non-Watson-Crick DNA structures, such as the Holliday junctions that result from 
DNA strand exchange during homologous recombination or repair of stalled replication forks 
(Risinger & Groden, 2004). Several RecQ helicases have been coupled to genomic instability 
disorders that predispose patients to tumor development, e.g. BLM, RECQL4 and WRN, which 
are responsible for Bloom syndrome, Rothmund-Thomson syndrome and Werner syndrome, 
respectively (Risinger & Groden, 2004).  
The FANCJ helicase is phosphorylated at serine 990 and binds the BRCT (BRCA1 C- 
terminal) domains of the BRCA1 protein during S phase of the cell cycle (Yu et al., 2003). This 
association seems to contribute to DSB repair via HR (Cantor et al., 2001). However, Bridge 
and colleagues (2005) showed that FANCJ functions independently of BRCA1 in the FA 
pathway. The type of structures that FANCJ preferentially binds to and unwinds is the forked 
duplexes (Gupta et al., 2005). In addition, FANCJ possesses an ATP-dependent DNA helicase 
that translocates in a 5’® 3’ direction and therefore, may directly repair damaged DNA (Cantor 
et al., 2004). Since normal monoubiquitination of FANCD2 was reported in FA-J cells, FANCJ 
is positioned downstream of this event in the FA pathway. Nevertheless, how FANCJ is 
connected to the FA pathway remains to be determined. 
 
 
4.5. Evolution of the FA genes 
 
An important limitation in understanding the molecular basis of FA is the lack of conservation 
of the FA proteins in lower eukaryotes (non-vertebrates) that could provide genetic models.  
The FANCA, FANCB, FANCC, FANCE, FANCF and FANCG genes are only conserved in 
vertebrates (chordata) implying that they have originated later during evolution (Figure 3). In 
addition, these FA genes encode novel proteins that lack sequence homologies or domains with 
known function. Therefore, orthologs of the human FA proteins with a high evolutionary 
distance have been looked for in order to find conserved residues/domains that highlight their 
biological importance (Blom et al., 2002, 2004). Orthologs are genes in different species that 
have originated from a common ancestral gene early in evolution and are thereby likely to 
perform a similar function. In fact, most of the FA proteins have been found in lower 
vertebrates, such as in zebrafish (Danio rerio) (Titus et al., 2006) and amphibia (Xenopus 
laevis) (Chapter 5; Sobeck et al., 2006). Moreover, FANCG orthologs have been used for the 
identification of multiple TPR (tetratricopeptide repeat) motifs essential for FANCG (Blom et 
al., 2002, 2004).  
The identification of more FA genes has, however, modified the notion that the FA pathway 
evolved late in evolution. Orthologs of some FA genes have been found in lower eukaryotes 
and even in archaebacteria, suggesting a possible conservation of the FA pathway throughout 
evolution (see Figure 3). These include the FANCD2 gene, which has orthologs in the fruit fly 
Drosophila melanogaster, in the nematode Caenorhabditis elegans and even in the plant 
Arabidopsis thaliana, but is absent in yeast (Timmers et al., 2001; Castillo et al., 2003; Dequen 
et al., 2005). Another example is FANCM (Meetei et al., 2005), which has orthologs in 
archaeabacteria and in yeast, Hef and MPH1, respectively. The first FANCM ortholog, Hef, is a 
DNA repair protein that contains both helicase and endonuclease activities and is able to restore 
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stalled replication forks (Komori et al., 2004). The second ortholog, MPH1, is known to possess 
a DNA helicase activity and participates in an error-free DNA damage bypass pathway 
(Prakash et al., 2005). Therefore, FANCM may also be part of these DNA repair mechanisms 
that protect the genome. 
 
 
 
 
 
Figure 3. Phylogenetic relationships of several model species (boxes) used in biomedical research*. All FA 
proteins are present in chordata. However, the FANCD2 protein is also found in metazoa and plants, and the 
FANCM protein in archaebacteria and yeast, suggesting an evolutionary conservation of the FA pathway. 
*From Blom et al., 2002. 
 
 
 
 
5. FA AND CARCINOGENESIS 
 
The precise role of the FA pathway in the etiology of hematopoietic failure and cancer 
formation in FA patients is an issue that is still under debate. However, it is well documented 
that carcinogenesis requires multiple genetic events and that FA patients are ahead of 
individuals without germline mutations in the carcinogenesis process (Tamura et al., 2004). The 
bialellic inactivation of one of the FA genes might increase the mutation rate required for 
cancer progression. Similarly, somatic disruption of the FA pathway could also be involved in 
the origin of sporadic tumors in the general population (for review, see Lyakhovich & Surrallés, 
2005). Indeed, a normal somatic cell could acquire malignant characteristics resulting from the 
accumulation of genetic alterations. These alterations can occur either “spontaneously” by 
endogenous substances (e.g. oxygen-reactive species) or under the influence of exogenous 
damaging factors (chemicals, sun or ionizing radiations), or by epigenetic mechanisms of gene 
silencing  (Figure 4) (Loeb, 2001; Loeb et al., 2003). 
The FA pathway might be critically implicated in the development of sporadic cancer 
progression. One of the first indications of this direct involvement resulted from the finding that 
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FANCF is inactivated by promoter hypermethylation in a subset of ovarian epithelial cancers 
(Taniguchi et al., 2003; Wang et al., 2006). FANCF gene silencing and disruption of the FA 
pathway may contribute to chromosome instability and selective cisplatin sensitivity observed 
in these tumors. Epigenetic silencing of FANCF by aberrant methylation of multiple CpG 
islands in the FANCF promoter might be an important mechanism in sporadic malignancies, as 
it was found in several other types of cancer, such as non-small-cell lung cancer (NSCLC), head 
and neck squamous carcinomas (HNSCC), cervical carcinomas and also in a case of sporadic 
AML (Tischkowitz et al., 2003; Marsit et al., 2004; Narayan et al., 2004). 
 
 
 
 
 
Figure 4. Causes, cellular responses and consequences of DNA damage. 
Slightly modified from van Gent et al., 2001. 
 
 
 
Another significant finding that implicates the FA pathway in cancer development, is the 
increased risk of Fancd2-deficient mice to develop epithelial cancers, mainly breast, ovarian, 
and liver cancers (Houghtaling et al., 2003).  
The high incidence of AML in FA patients (15 000-fold) suggests that FA genes may play a 
specific role in non-FA individuals with AML. Acquired rather than inherited disruption of the 
FA pathway, by deletion, reduction of expression or point mutation in a FA gene may represent 
an early event in the development of sporadic AML (Xie et al., 2000; Condie et al., 2002). 
Indeed, dysfunction of the FANCA protein has been found in sporadic AML cases (Lensch et 
al., 2003; Tischkowitz et al., 2004).  
Genetic alterations of the FANCD1/BRCA2, FANCC and FANCG genes seem also to 
predispose cells toward malignant transformations in the general population. Inactivation of one 
of these genes occurs in 5-10% of sporadic pancreatic carcinomas (Goggins et al., 1996; van der 
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Heijden et al., 2003, 2004; Couch et al., 2005). Similarly, inherited mutations in FANCC and 
FANCG appear to be implicated in a subset of patients with a family history of pancreatic 
cancer (van der Heijen et al., 2003). With the exception of families with germline mutations in 
the FANCD1/BRCA2 gene, which predisposes to a number of epithelial cancers, such as breast, 
ovary, prostate or pancreas (Turner et al., 2004; Wagner et al., 2004), there is little evidence for 
an increased risk of breast cancer in relatives of FA patients (Seal et al., 2003).  
In most cells, only a single functional copy of FANCB is present because of its location on 
chromosome X and the random inactivation of one X chromosome in females (Meetei et al., 
2004). FANCB, which is an essential component of the FA pathway, might potentially be 
inactivated by point mutation, deletion or methylation. Therefore, somatic mutational 
inactivation of FANCB could generate an FA-like cellular phenotype that might contribute to 
the oncogenesis process. 
Importantly, patients harboring tumors with a defect in the FA pathway are expected to be 
sensitive to DNA cross-linking-based therapy (such as cisplatin) and are therefore curable 
(Lyakhovich & Surrallés, 2005). Recent encouraging data from van der Heijden and colleagues 
(2005) support the use of cross-linker drugs in clinical trial for those patients. One might 
imagine the potential therapeutic use of drugs that enhance cross-linker sensitivity of tumors 
(e.g. by FA pathway inhibitors) to the cytolytic effect of cisplatin in specific targeted cells. 
 
 
 
6. TREATMENT 
 
The treatments offered to FA patients are mainly directed to their hematological complications. 
In the short term, the use of hematopoietic growth factors, such as G-CSF and GM-CSF 
(granulocyte-macrophage colony-stimulating factor) can improve blood counts. However, their 
effects on the rate of hemoglobulin and platelet stimulation are variable and often disappointing 
(Guinan et al., 1994; Rackoff et al., 1996). Androgen therapy is another therapeutic alternative, 
which can be applied in conjunction with hematopoietic growth factors. However, most of 
treated patients become refractory over the long term and, because of the treatment, may have a 
higher risk to develop liver adenomas and tumors (Young & Alter, 1994).  
The treatment of choice for FA is bone marrow transplantation (BMT) with a histocompatible 
sibling donor, which replaces the defective stem cells. The stem cells of the donor can be 
collected from bone marrow, peripheral blood or umbilical cord blood. The standard protocol 
for transplantation has to be adjusted for FA patients, due to their hypersensitivity to 
cyclophosphamide, an alkylating agent used to deplete the body from host BM and blood cells 
prior to transplant. In histocompatible HLA-matched siblings, this therapy is very effective with 
a success rate of ~70% (Guardiola et al., 1998). However, for patients without HLA-compatible 
sibling donor, the prognosis is relatively poor with 33% survival at 3 years (Guardiola et al., 
2000). Strikingly, the overall survival prognosis for FA individuals is also poor, where the 
median survival age is reduced to ~20 years (range 0-50 years) (Joenje & Patel, 2001).  
Even though the BMT successfully cures the bone marrow failure, FA patients still have a 
high risk to develop solid tumors. In addition, treatment of leukemia and/or solid tumors in FA 
patients is complicated because of their hypersensitivity to the cross-linking chemotherapeutic 
agents (e.g. MMC, cisplatinum and cyclophosphamide).    
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Gene therapy represents an attractive substitute for patients lacking HLA-matched donors. 
This approach attempts to transfer, ex vivo, a normal cDNA copy of the defective FA gene into 
the hematopoietic progenitors or stem cells collected from the patient in a viral vector. Since 
blood from mosaic FA patients displays a selective growth advantage for wild-type cells 
(reverted from the pathogenic allele), the FA cells corrected by gene therapy may also have 
proliferative advantage in vivo (Waisfisz et al., 1999b; Cohen-Haguenauer et al., 2006). A 
recent study has given promising results in transduced cells with a lentiviral vector and to date 
this technology is adapted for FA patients (Galimi et al., 2002). However, like BMT, gene 
therapy would not correct physical abnormalities nor reduce the risk to develop solid tumors.  
 
*1IFAR: http://clinfo.rockefeller.edu/fanconi/ptrecrt.html 
*2Mutation status: www.rockefeller.educ/Fanconi/mutate/ 
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7. OUTLINE OF THE THESIS 
 
The discovery of new FA genes provides a great opportunity to understand the molecular basis 
of FA and could also be helpful for clinical diagnosis, gene therapy and preventive measures for 
patients and families with FA. In the present thesis, we have isolated the Fanconi anemia group 
E gene, FANCE, by expression cloning and functional complementation of MMC 
hypersensitivity in FA-E cells (Chapter 2). 
 
Mutation screening in an FA gene can define important domains in the protein and on the 
biochemical features of the FA pathway. Moreover, a particular FA genotype might guide the 
clinical management of patients. In Chapter 3, we describe the identification of a novel 
homozygous FANCE missense mutation (R371W) in two patients belonging to 
complementation group E.  
 
The FANCF gene was previously described (de Winter et al., 2000a). Both FANCE and 
FANCF proteins are ‘orphans’, with unknown function. To gain more insight in the molecular 
functions of these two FA proteins, subcellular localization, domain structures and protein 
interactions were examined. In Chapter 4, we investigated the nuclear localization of the 
FANCE protein and analyzed the domains involved in the interaction with its two direct binding 
partners: FANCC and FANCD2. To determine functionally important domains in the FANCF 
protein, we performed an extensive mutagenesis study (Chapter 5). Since functional domains in 
proteins are often highly conserved between species, we used a Xenopus leavis FANCF 
homolog to predict important residues and domains in FANCF.  
 
Finally, in the General Discussion (Chapter 6) a model for the assembly of the FA core 
complex is presented. In addition, the possible function of the FA pathway in DNA repair is 
discussed. 
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FANCONI ANEMIA (FA) is an autosomal recessive chromosomal instability syndrome with at 
least seven different complementation groups. Four FA genes (FANCA, FANCC, FANCF, and 
FANCG) have been identified, and two other FA genes (FANCD and FANCE) have been 
mapped. Here we report the identification, by complementation cloning, of the gene mutated in 
FA complementation group E (FANCE). FANCE has 10 exons and encodes a novel 536-amino 
acid protein with two potential nuclear localization signals. 
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INTRODUCTION 
 
Fanconi anemia (FA) is characterized by bone marrow failure, developmental abnormalities, 
cancer predisposition and cellular hypersensitivity to DNA cross-linking agents such as 
mitomycin C (Auerbach et al. 1998 [MIM 227650]). Complementation analysis has indicated 
that mutations in at least 7 different genes can cause FA (Joenje et al. 1997, 2000). Four FA 
genes have been identified: FANCA (Fanconi Anemia/Breast Consortium 1996; Lo ten Foe et 
al. 1996 [MIM 227650]), FANCC (Strathdee et al. 1992 [MIM 227645]), FANCF (de Winter et 
al. 2000 [MIM 603467]) and FANCG (de Winter et al. 1998 [MIM 602956]). Intriguingly, none 
of these genes has revealed any decisive clue towards a molecular function of the FA pathway, 
since they encode novel proteins that lack significant functional domains. The recently 
described homology between FANCF and the RNA binding protein ROM (de Winter et al. 
2000) appeared to be nonsignificant, because mutations in the FANCF region homologous to 
ROM did not affect the function of FANCF (J.P. de Winter, unpublished data). Two other FA 
genes, FANCD and FANCE, have been mapped to chromosome 3p25.3 (Whitney et al. 1995; 
Hejna et al. 2000 [MIM 227646]) and 6p21-22 (Waisfisz et al. 1999 [MIM 600901]), 
respectively.  
 
Here we report the cloning of a cDNA representing FANCE, by complementation of the FA-
E lymphoblastoid cell line EUFA410 (Waisfisz et al. 1999) with an episomal expression library 
(Strathdee et al. 1992). Following selection for library uptake in hygromycin-containing 
medium (100 mg/ml) and subsequent selection for resistance to mitomycin C (15 nM), 4 of the 
12 cDNA clones that we recovered from the pool of complemented cells had identical inserts of  
~2.5 kb. Secondary transfection of one of these cDNA clones (clone10 [AF265210]) into 
EUFA410 cells again complemented their MMC-hypersensitive phenotype (Fig. 1a). The 
cDNA insert has a 1,611-nt open reading frame, encoding a 536-amino acid protein (Fig. 1b). 
The predicted FANCE protein contains two potential nuclear localization signals, but, like the 
other FA proteins, lacks any significant homology to other proteins.  
 
The Stanford high-resolution TNG3 radiation-hybrid panel was used to position FANCE 
between microsatellite markers D6S439 and D6S1645 in agreement with the genetic map 
location of FANCE (Waisfisz et al. 1999). The FANCE cDNA appeared identical to a human 
genomic DNA sequence (clone 109F14 [Genbank accession number AL022721]; Tripodis et al. 
2000) on chromosome 6p21.2-21.3. A comparison between this genomic DNA sequence and 
the FANCE cDNA revealed that the FANCE gene has 10 exons spanning ~15 kb of genomic 
sequence. FANCE appears to be located between the genes encoding the 60S ribosomal protein 
RPL10A (Csa-19) and a ZNF127 like protein, a region where cDNA selection, exon trapping, 
and exon prediction programs failed to detect a gene (Tripodis et al 2000).  
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Figure 1. Complementation of MMC hypersensitivity in FA-E lymphoblastoid cell line EUFA410, and 
FANCE protein sequence. a, MMC hypersensitivity of FA-E cell line EUFA410 is corrected after 
transfection of FANCE cDNA clone 10. HSC93, wild type control. b, Amino acid sequence of the FANCE 
protein. Nuclear localization signals as predicted by PSORT II (Nakai and Horton, 1999) are shown in bold 
and underlined. 
 
 
 
Mutation screening of the FANCE gene revealed a homozygous C®T transition in exon 2 of 
EUFA410, which changes codon 141 into a stop codon (R141X; table 1). The parents were 
heterozygous for this mutation. In the FA-E reference cell line EUFA130 (Joenje et al. 1997) a 
homozygous C®T nonsense mutation was found in codon 119 (Q119X; table 1). The parents 
and unaffected brother were heterozygous for this mutation. A homozygous mutation IVS5-
8G®A was detected in genomic DNA from FA-E cell line EUFA622 (Waisfisz et al. 1999), 
which creates an alternative splice acceptor site (table 1). Sequence analysis on cDNA derived 
from EUFA622 indicated that this mutation results in false splicing and incorporation of 6 
nucleotides from intron 5, including an in-frame stop codon. These findings confirmed the 
identity of the FANCE gene. 
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    Table 1. Mutations in Three FA-E Patients 
Patient Ancestry Mutation Consequence for protein 
EUFA130 Turkey 355 C®T Q119X 
EUFA410 Bangladesh 421 C®T R141X 
EUFA622 Turkey IVS5-8G®Aa R371_I372insLX 
Note, nucleotide numbering starts at translation initiation site. All these patients are homozygous for 
the indicated mutations. 
a Mutation IVS5-8G®A (underlined) ttagctgtag ATC CTC creates an alternative splice acceptor site, 
that results in false splicing and insertion of 6 nucleotides from intron 5 (underlined), including an 
in-frame stop codon GGA CGG ctg tag ATC CTC. 
 
 
Our data show that FANCE encodes a novel protein with two nuclear localization signals, 
which strongly suggests that the pathway defective in FA patients has a nuclear function. 
Although recent evidence indicates that the FA pathway might be involved in cellular 
detoxification (Kruyt et al. 1998), transcriptional repression (Hoatlin et al. 1999) or STAT1 
activation (Pang et al. 2000), the precise nature of this pathway still remains to be elucidated.  
 
Given that FANCE is localized in a region containing the HLA class I genes of the major 
histocompatibility complex (Waisfisz et al. 1999; Tripodis et al. 2000), group E patients are 
very unlikely to have an HLA-matched unaffected sibling donor for successful bone marrow 
transplantation. The cloning of FANCE now makes this group of patients prime candidates for 
gene-therapy trials aiming at genetic correction of their bone marrow failure (Liu et al. 1999).  
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FANCONI ANEMIA (FA) is a recessive chromosomal instability syndrome characterized by 
bone marrow failure, diverse congenital malformations and cancer predisposition. To date, 
twelve FA complementation groups (A-C, D1, D2, E-G, I, J, L and M) have been assigned and 
eleven associated genes have been identified. FANCE is the gene mutated in FA 
complementation group E. Here we report a novel FANCE mutation (1111C®T) leading to an 
amino acid substitution (R371W) and disruption of the FA pathway. The defective FANCE 
protein is undetectable by immunoblot analysis. This FANCE missense mutation was found 
homozygous in a German and Dutch FA-E patient. The possibility of an ancestral founder 
mutation in FANCE remains to be elucidated.    
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INTRODUCTION 
 
Fanconi anemia (FA) is rare recessive chromosomal instability syndrome characterized by bone 
marrow failure, congenital abnormalities and cancer predisposition (for reviews, see Joenje & 
Patel, 2001; D’Andrea & Grompe, 2003). The cells from FA patients are hypersensitive to 
DNA cross-linking agents, such as mitomycin C (MMC) and diepoxybutane, which suggest a 
role of these proteins in the repair of DNA interstrand cross-links. To date, 12 FA 
complementation groups have been described (Levitus et al., 2004) and 11 associated genes 
have been identified: FANCC (Strathdee et al., 1992), FANCA (FAB, 1996; Lo Ten Foe et al., 
1996), FANCG (de Winter et al., 1998), FANCF (de Winter et al., 2000a), FANCE (de Winter 
et al., 2000b), FANCD2 (Timmers et al., 2001), FANCD1/BRCA2 (Howlett et al., 2002), 
FANCL (Meetei et al., 2003), FANCB (Meetei et al., 2004), FANCJ (Levitus et al., 2005; 
Levran et al., 2005; Litman et al., 2005) and FANCM (Meetei et al., 2005).  
 
Most FA patients belong to complementation group A (65%), G (13%) and C (10%), in a 
population of 241 subtyped FA families (classified by the European Fanconi Anemia Research 
Programme), while the other subtypes are very rare (Levitus et al., 2004). Nevertheless, the 
worldwide prevalence of one FA complementation group compared to another often varies with 
ethnic background (Joenje & Patel, 2001). For instance, different founder mutations in FANCA 
were reported in the Afrikaner population of South Africa (Tipping et al., 2001) and in Gypsy 
families from Spain (Callén et al., 2005), while the majority of the FA Ashkenazi-Jewish 
families share a common mutation in FANCC (Whitney et al., 1993). In addition, the clinical 
manifestations and outcomes of FA patients are also variable between and inside 
complementation groups, and could be associated to a particular type of mutation in an FA gene 
(Faivre et al., 2000; Kutler et al., 2003). Therefore, the identification of a mutation in an FA 
gene could significantly improve the clinical management of those patients.        
 
The FA complementation group E is a rare subtype. To date, only seven FA-E patients have 
been identified worldwide (Levitus et al., 2004; Ameziane et al., 2006). FANCE is the gene 
defective in the FA complementation group E and is localized to chromosome band 6p21.2-21.3 
(Waisfisz et al., 1999; de Winter et al., 2000b). The FANCE gene has 10 exons spanning ~ 15 
kb of genomic DNA and a 1.611-nucleotide open reading frame encoding a protein of 536-
amino acids (de Winter et al., 2000b). Here we report a novel FANCE mutation in two FA-E 
patients (1111C®T) that leads to an amino acid change in codon 371 (R371W). Intriguingly, 
these 2 patients originate from Germany (EUFA279) and The Netherlands (EUFA1278) and 
therefore, may represent a founder mutation in FANCE. The results of the present report are 
included in Ameziane et al., 2006.  
 
 
MATERIALS AND METHODS 
 
Patients, cell lines and complementation analysis 
The FA diagnosis of the patients was based on clinical symptoms and chromosomal breakages 
tests. Cell fusion studies (as described in Joenje et al., 1995), functional complementation, 
protein analysis and sequencing allowed us to assign the two FA patients EUFA279 and 
EUFA1278 to complementation group E. Lymphoblastoid cell lines were established from 
46     Chapter 3                                                                           
 
 
blood by Epstein-Barr virus (EBV) transformation. The MMC-induced growth inhibition test 
was performed as previously described (Ishida et al., 1982; Joenje et al., 1986). 
 
Sequencing and mutation analysis of FANCE 
Genomic DNA was isolated from lymphoblastoid cells by standard procedures and total RNA 
by using the RNase Out ribonuclease (Invitrogen). To synthesize cDNA we used Superscript II 
RNase H reverse transcriptase (Invitrogen) and Oligo dT priming (Roche) according to standard 
protocols. Sequence change in patient EUFA279 was identified at the genomic level and 
confirmed on cDNA by direct sequencing using the Thermo Sequenase Cy5.5 dye terminator 
cycle sequencing kit (Amersham) and the Visible Genetics OpenGene automatic sequencer 
(Visible Genetics Inc, Toronto, Ontario, Canada) to analyze the products. Mutation screening in 
the patient EUFA1278 was done by the denaturing high-performance liquid chromatography 
(DHPLC) approach (Ameziane et al., 2006). 
 
Protein analysis 
Cell lysates (~400 000 cells) from lymphoblastoid cell lines were obtained as previously 
described (Léveillé et al., 2004) and proteins were separated on SDS-polyacrylamide gel. 
Proteins were transferred to a PVDF membrane and immunoblotted with FANCE antibody 
(kindly provided by Dr. K.J. Patel).      
 
 
RESULTS AND DISCUSSION 
 
The FA patients EUFA279 and EUFA1278 were diagnosed on the basis of their clinical 
features and hypersensitivity to MMC in a chromosomal breakage test. Genetic subtyping by 
cell fusion, functional complementation, sequencing and immunoblotting experiments showed 
that these two patients belong to the FA complementation group E. As shown in Figure 1, 
transfection of wild-type FANCE cDNA in a lymphoblastoid cell line of patient EUFA279 
corrected the MMC hypersensitive phenotype of this cell line, indicating that patient EUFA279 
belongs to complementation group E and has a defect in the FANCE gene.  
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Figure 1. Complementation of the 
MMC hypersensitive phenotype of 
the FA-E lymphoblastoid cell line 
EUFA279 after transfection with 
FANCE cDNA. Cell line HSC93 is 
shown as a wild-type control. 
 
                                                                      FANCE mutation in two patients         47 
 
In both patients, mutation screening of the FANCE gene revealed a homozygous 1111C®T 
transition at the end of exon 5, which results in a missense mutation in codon 371 (R371W). 
Sequence analysis on cDNA from patient EUFA279 showed the same result, which indicates 
that this particular mutation in FANCE did not affect the splicing of FANCE RNA. The 
missense mutation R371W in these two patients has not been reported in other FA-E patients 
and is the first amino acid substitution found in FANCE (Table 1). The arginine at position 371 
is a lysine in Zebrafish FANCE amino acid sequence (data not shown), implying that those two 
conserved positively charged residues might be important for the function and/or stability of 
FANCE. The other FANCE disease-associated mutations result in early stop codons. Table 1 
shows the spectrum of FANCE mutations in known FA patients.  
 
 
TABLE 1. Mutations in FANCE 
FA-E Patient   Ancestry         Mutation         Consequence                     Reference 
                                                                       for protein                
EUFA130      Turkey     355C®T         Q119X         de Winter et al., 2000b 
EUFA279      Germany 1111C®T        R371W                  current study 
EUFA410      Bangladesh 421C®T          R141X                       de Winter et al., 2000b 
EUFA622      Turkey            IVS5-8G®A       R371_I372insLX      de Winter et al., 2000b 
EUFA1278     Netherlands    1111C®T        R371W                 current study     
EUFA1327   France     91C®T            Q31X                 Ameziane et al., 2006 
EUFA1331            Turkey           IVS5-8G®A        R371_I372insLX      Ameziane et al., 2006 
 
 
 
To determine if the altered FANCE proteins were expressed in FA-E patients with different 
types of mutations, we performed an immunoblotting analysis on patients EUFA279 (R371W), 
EUFA410 (R141X) and EUFA1331 (IVS5-8G®A) (Fig. 2). The FANCE proteins were 
completely absent in the lymphoblastoid cell lines of all patients, which might be due to a rapid 
degradation of these proteins. Arginine 371 is predicted to be part of a a-helix and possibly the 
change of this amino acid might affect this helix and destabilize the FANCE protein. 
 
Some ethnic populations have a higher frequency of FA due to ancestral founder mutations 
and isolation (Joenje & Patel, 2001). The two FA-E patients reported in this study come from a 
similar geographic area (patient EUFA279 is from Germany and patient EUFA1278 is from 
The Netherlands), and therefore, might share a common ancestor. An extensive genealogy study 
for both families is currently being performed.    
 
The small number of patients within the FA complementation group E makes it difficult to 
correlate the genotype and the clinical phenotype of these patients. Although it seems that the 
FA-E subtype has a higher prevalence of somatic abnormalities and that three of five patients 
showed malformations of the central nervous system (Faivre et al., 2000). The type mutation in 
an FA gene could also be a good indication for the clinical management of the patients. For 
example, different classes of mutations in FANCC revealed that the patients with intron 4 or 
exon 14 mutations have a poor hematologic and survival outcomes compared to patients with 
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exon 1 mutation (Kutler et al., 2003). It will be also relevant to compare different classes of 
mutation in FANCE with the clinical outcomes of these patients. Therefore, the identification of 
a novel mutation in FANCE could provide additional useful information for the clinical 
management of these patients.    
 
 
 
Figure 2. FANCE immunoblotting analysis. FANCE is absent in lymphoblastoid cell lines of FA-E 
patients EUFA279, EUFA410 and EUFA1331. HSC93 cell line is shown as a wild-type control. 
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FANCONI ANEMIA (FA) protein FANCE is an essential component of the nuclear FA core 
complex, which is required for monoubiquitination of the downstream target FANCD2, an 
important step in the FA pathway of DNA cross-link repair. FANCE is predominantly localized 
in the nucleus and acts as a molecular bridge between the FA core complex and FANCD2, 
through direct binding of both FANCC and FANCD2. At present, it is poorly understood how 
the nuclear accumulation of FANCE is regulated and therefore we investigated the nuclear 
localization of this FA protein. We found that FANCE has a strong tendency to localize in the 
nucleus, since the addition of a nuclear export signal does not interfere with the nuclear 
localization of FANCE. We also demonstrate that the nuclear accumulation of FANCE does not 
rely solely on its nuclear localization signal motifs, but also on FANCC. The other FA proteins 
are not involved in the nuclear accumulation of FANCE, indicating a tight relationship between 
FANCC and FANCE, as suggested from their direct interaction. Finally, we show that the 
region of FANCE interacting with FANCC appears to be different from the region involved in 
binding FANCD2. This strengthens the idea that FANCE recruits FANCD2 to the core 
complex, without interfering with the binding of FANCC.  
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INTRODUCTION 
 
Fanconi anemia (FA) is a recessive inherited chromosomal instability disorder characterized by 
congenital anomalies, progressive bone marrow failure, and predisposition to acute myeloid 
leukemia and squamous cell carcinomas (for review, see Refs. [1-3]). FA cells display 
excessive chromosomal aberrations and hypersensitivity to DNA cross-linking agents such as 
mitomycin C (MMC) and diepoxybutane (DEB), indicative of a molecular defect in DNA-
damage response.  
 
To date, 12 FA complementation groups have been identified and all the associated genes 
have been cloned (FANCA, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -J, -L and -M) [4-15], except 
for FANCI [16]. The FA proteins collaborate in a common pathway in which the FANCA, -B, -
C, -E, -F, -G, -L and -M proteins assemble in a nuclear core complex that functions as an 
ubiquitin ligase for FANCD2 [12,14,17]. The monoubiquitinated form of FANCD2 colocalizes 
with proteins involved in DNA repair (such as BRCA1, RAD51, and NBS1) during S-phase or 
in response to DNA damaging agents [18,19]. In addition, the FANCD2 protein binds double 
strand DNA ends and Holliday junctions [21], and assembles with FANCD1/BRCA2 and 
FANCE in a stable chromatin complex [22]. The USP1 protein appears to be the 
deubiquitinating enzyme of FANCD2 and may therefore play a critical role in the regulation of 
the FA pathway [20]. The FA proteins have been implicated in the repair of interstrand cross-
link (ICL) lesions through diverse repair pathways, such as homologous recombination (HR), 
translesion synthesis and the BLM helicase pathway [23-27]. Importantly, recent studies 
showed that the FANCJ and FANCM proteins have a helicase and DNA translocase activity, 
respectively [14,15]. These findings indicate that FA proteins may play a direct role in DNA-
damage response.  
 
The specific functions of the FA proteins in the FA core complex and the structural features 
of the various protein-protein interactions within this complex are not fully understood. 
FANCC, one of the FA core complex components, has been shown to localize in both 
cytoplasmic and nuclear compartments of the cell [28-31]. The nuclear localization of FANCC 
is crucial for the function of the FA core complex and depends on the presence of FANCE 
[32,33]. FANCE directly interacts with both FANCC and FANCD2 and, consequently, links the 
downstream FANCD2 protein to the putative ligase activity of the nuclear FA core complex 
[33-35]. The FANCE protein contains 2 putative nuclear localization signals (NLS) [9] and 
localizes to nuclear foci [33], but it is unclear how the nuclear localization of FANCE is 
regulated. A better insight in the nuclear accumulation of the FANCE protein will improve our 
understanding of the FA core complex assembly.  
 
Here we present a study on the nuclear localization of FANCE and the interaction between 
FANCE, FANCC and FANCD2. We found that the FANCE and FANCC proteins are 
functionally linked in that they require each other to be stable in the nucleus of the cell. The 
nuclear accumulation of FANCE depends not only on its nuclear localization signals, but also 
on FANCC, and not on the other FA proteins. By mammalian two-hybrid assay, we determined 
that different regions of FANCE seem to mediate the direct interactions with FANCC and 
FANCD2. 
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MATERIALS AND METHODS 
 
1. Cell culture, transfection and MMC assay   
Epstein-Barr virus (EBV)-immortalized lymphoblasts were maintained in RPMI 1640 media 
supplemented with 1 mM glutamine (Invitrogen, Carlsbad, CA, USA) and 10% fetal calf serum 
(FCS) (Invitrogen). Lymphoblastoid cell lines were transfected by electroporation using an 
ECM830 electrosquareporator (BTX, San Diego, CA, USA) and cultured in selection media 
containing hygromycin B (100 µg/ml; Roche, Basel, Switzerland). The MMC-induced growth 
inhibition assays were performed as previously described [36,37]. The HeLa cells were grown 
in Dulbecco modified Eagle medium (DMEM) supplemented with 10% FCS and the fibroblasts 
(BeBu and FA-C fibroblasts EUFA1233) were maintained in F10 medium.  
 
2. Plasmid constructs 
A wild-type or a mutated nuclear export signal (NES) was cloned to the C-terminus of pSK-
FANCE [see Ref. 38] and then subcloned in the pEGFP-N1 expression vector (Clontech, Palo 
Alto, CA, USA). For the generation of the FANCE construct in which the nuclear localization 
signal 1 was mutated (mNLS1), we used the QuickChange site-directed mutagenesis kit 
(Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions. Oligonucleotides 
with mutations in NLS2 were used to create FANCE-mNLS2 and FANCE mNLS1-2 by PCR 
using pN1-FANCE-GFP and pN1-FANCE-mNLS1-GFP as a template. All FANCE mutant 
constructs were subcloned into the episomal expression vector pMEP4 (Clontech). The FANCE 
fragments used in the mammalian two-hybrid assay were generated by using internal restriction 
sites in FANCE or by PCR with primers that contained specific restriction sites and subcloned 
into pM-GAL4 DNA-binding domain and pVP16-GAL4 activation domain vectors (Clontech). 
The sequences of the FANCE NLS mutants and the correct reading frame of all the FANCE 
fragments were verified using the GeneAmp PCR system 9700 (Applied Biosystems) and 
analyzed on an ABI 3730 DNA analyzer (Applied Biosystems). 
 
3. DNA transfections and fluorescence microscopy analysis 
For transient transfections, 2.5 x 105 HeLa cells were seeded onto sterile glass coverlips in six-
well plates, and transfected with 1 µg of pEGFP-N1 alone (Invitrogen) or pEGFP-N1 encoding 
FANCE-GFP, FANCE-NES/mNES-GFP or FANCE NLS mutants using Lipofectamine Plus 
(Invitrogen), according to manufacturer’s guidelines. When indicated, FANCE constructs were 
cotransfected with pCMV-Flag-CRM1 (a generous gift from Dr. Jose A. Rodriguez, VUMC, 
Amsterdam). The primary wild type (BeBu) and FA-C (EUFA1233) fibroblast cell lines were 
transiently transfected with 1 µg of pN1-FANCE-GFP and pN1-FANCEmNLS1-2-GFP by 
electroporation (Amaxa). At 24h (HeLa cells) or 48h (fibroblasts) after transfection, cells with 
the EGFP-tagged proteins were fixed with 3.7% formaldehyde in PBS for 30 min, washed with 
PBS, and stained with the chromosomal dye Hoechst 33342 (Sigma, St. Louis, MO) for 30 min 
in order to counterstain the nuclei, and mounted onto microscope slides using Vectashield 
(Vector Laboratories, Inc., Burlingame, CA). Immunocytochemical detection of Flag-CRM1 
was performed with the anti-Flag M2 monoclonal antibody (Stratagene, La Jolla, CA) and an 
Alexa Fluor 594-conjugated goat anti-mouse secondary antibody (Molecular Probes, Eugene, 
OR), using a previously described immunostaining method [39]. Slides were examined under 
UV light on an inverted Leica DMIRB/E fluorescence microscope (Leica Heidelberg, 
Heidelberg, Germany). Images (magnification X 400) were collected using Leica Q500MC 
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Quantimet software V01.01 (Leica Cambridge Ltd., Cambridge, UK). To determine the 
subcellular localization of EGFP-tagged proteins, at least 50 transfected cells per sample were 
scored after coding and mixing the slides to ensure unbiased results. 
 
4. Mammalian two-hybrid analysis 
Human embryonic kidney cells 293 plated onto six-well plates were transiently transfected as 
previously described [40]. The full-length FANCE, FANCE with mutated NLS1-2 or the 
indicated FANCE fragments fused with either the GAL4 activation domain (AD) (pVP16; 
Clontech) or to the GAL4 DNA-binding domain (BD) (pM; Clontech) were assayed with either 
AD-FANCC or BD-FANCD2 (1 mg of each), jointly with a GAL4 driven reporter plasmid 
(G5E1bLUC, 0.2 mg). The luciferase activity of the reporter gene was monitored after 24h using 
a Dual-Luciferase Reporter Assay System (Promega) and a single tube luminometer (DLReady, 
Berthold Detection Systems), according to the manufacturer’s instructions. All GAL4 
constructs were sequenced to confirm the correct reading frame and each experimental data set 
was performed in triplicate to overcome the variability inherent to transfections. The expression 
of the GAL4 fusion FANCE deletion constructs was verified by immunoblotting. 
 
5. Subcellular fractionation, immunoprecipitation and immunoblotting 
The nuclear and cytoplasmic fractions of the lymphoblastoid cell lines were prepared as 
described [41]. Equal amounts of protein (20 mg), determined with a Bio-Rad protein assay 
(Hercules, CA), were separated on SDS-polyacrylamide gels and then transferred to PVDF 
membranes. Specific proteins were detected by immunoblotting with the indicated antibodies.  
 
 
RESULTS 
 
1. The nuclear accumulation of FANCE is not prevented by addition of an ectopic nuclear 
export signal  
 
Previous studies showed that FANCE is a nuclear protein and an essential component of the 
nuclear FA core complex [9,32,33]. To study the nuclear accumulation of FANCE, we first 
tried to interfere with its nuclear localization, by integrating an ectopic nuclear export signal 
(NES) into a FANCE-GFP fusion protein. We chose the leucine-rich NES motif from the 
inhibitor of cAMP-dependent protein kinase (PKI protein), and a mutated version (mNES) of 
this motif as a control (Fig. 1A). These motifs have previously been used successfully to 
interfere with the nuclear localization of FANCA [38]. Fluorescence microscopy revealed that 
both FANCE-GFP and FANCE-mNES-GFP proteins were present in the nuclear compartment 
of transiently transfected HeLa cells (Fig. 1B and D). Unexpectedly, the FANCE-NES-GFP 
fusion protein was also predominantly localized in the nucleus, although some cells showed 
positive staining in the cytoplasm as well (Fig. 1C). Consistent with these observations, 
FANCE-NES/mNES-GFP and FANCE-GFP proteins fully complemented the MMC 
hypersensitive phenotype of the lymphoblastoid FA-E cell line EUFA410 (data not shown), 
indicating that these proteins are functional. It seems therefore that the NES motif is not able to 
export all the nuclear FANCE protein to the cytoplasm or may be masked. The nuclear export 
receptor CRM1 binds nuclear proteins containing leucine-rich NES, such as the PKI NES, and 
exports them from the nucleus in the cytoplasm [42,43]. To investigate whether our ectopic 
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NES motif is functional, we transiently co-transfected Flag-CRM1 with FANCE-NES-GFP into 
HeLa cells. Fluorescence microscopy showed that, when co-expressed with CRM1, the 
FANCE-NES-GFP protein was completely relocalized to the cytoplasm, while the FANCE-
mNES-GFP fusion protein was still located in the nucleus (Fig. 1F and G). These results 
indicate that the NES motif coupled to FANCE is functionally active and dependent on the 
CRM1-pathway but insufficient to export FANCE out of nuclear compartment in vivo. 
Apparently, FANCE has a strong tendency to localize in the nucleus. 
 
 
2. The nuclear localization of FANCE is not entirely dependent on its NLS motifs  
 
The FANCE protein has no homology to other known proteins, but 2 putative nuclear 
localization signals (NLS) have been described [9]. The NLS regions in human FANCE 
(hFANCE) are evolutionary conserved between zebrafish, puffer fish and mouse FANCE. The 
sequence alignment of the NLS motifs revealed that the first NLS motif (KRRK; amino acids 
199-202) is more conserved than the second motif (PKRLRCW; amino acids 222-228) (Fig. 2). 
To test the involvement of the NLS motifs in the nuclear localization of FANCE, we made 
single and double FANCE NLS mutants. In each motif, three positively charged residues were 
changed into alanine (Fig. 2). We analyzed the subcellular localization of the FANCE mutants 
in transiently transfected HeLa cells and found that the FANCEmNLS1-GFP protein was 
exclusively localized in the nucleus, as wild-type FANCE-GFP (Fig. 3A and B). The 
FANCEmNLS2-GFP protein was predominantly located in the nucleus but also showed a weak 
cytoplasmic staining (Fig. 3C and E). Interestingly, the double NLS1-2 FANCE mutant was 
localized diffusely and equivalently in both nuclear and cytoplasmic compartments (Fig. 3D 
and E). All FANCE NLS mutant proteins were able to complement the MMC hypersensitivity 
of the FA-E lymphoblasts EUFA410 (data not shown), which is consistent with their nuclear 
localization. These results suggest that the NLS2 motif has a stronger effect on the nuclear 
accumulation of FANCE than NLS1 and show that the nuclear localization of FANCE does not 
rely solely on its NLS motifs.  
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Figure 1. The ectopic nuclear export signal is functional but insufficient to export FANCE out of the 
nucleus in vivo. (A) Schematic representation of wild-type FANCE-GFP fused to the PKI (protein kinase 
inhibitor) NES and to a mutated version (mNES). (B-D) Subcellular distribution of wild-type FANCE-
GFP, FANCE-NES-GFP and FANCE-mNES-GFP proteins transiently transfected in HeLa cells. (E-G) 
Subcellular distribution of wild-type FANCE-GFP, FANCE-NES-GFP and FANCE-mNES-GFP proteins 
co-transfected with Flag-CRM1 into HeLa cells. Counterstaining with Hoechst is performed to visualise 
the nuclei. Magnification 400x. 
 
 
 
hFANCE           KRRK PKRLRCW
zfFANCE          KKRK PQSKKVK
pfFANCE          KRKK PKVDACR
mFANCE          KRTK PKRFRGCE
mutated NLS1-2 KAAA PAALACW
1 536
NLS1 NLS2
199 222
hFANCE
 
Figure 2. The NLS motifs in FANCE are well conserved among different species. Multiple alignment of 
the NLS sequences in FANCE from different species; human (hFANCE), zebrafish (zfFANCE), 
pufferfish (pfFANCE) and mouse (mFANCE). The italic characters indicate different amino acids in the 
NLS motifs from the indicated species. The amino acid changes in the mutated NLS1 and NLS2 motifs of 
FANCE are depicted in bold and are underlined. 
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Figure 3. Mutations in the NLS motifs of FANCE do not completely affect its nuclear localization. (A-D) 
Subcellular distribution of the indicated GFP-fusion proteins transfected into HeLa cells and analyzed by 
fluorescence microscopy. (E) Quantification of the localization studies. The graphic represents the mean 
values ± standard deviation (S.D.) of two independent experiments. The nuclear (N) or nuclear and 
cytoplasmic (NC) localization of FANCE and NLS mutant proteins were scored blind.   
 
 
 
3. FANCE and FANCC are reciprocally essential for their nuclear accumulation  
 
Since the double mutant FANCEmNLS1-2 is still localized in the nucleus of the transiently 
transfected HeLa cells, we inferred that other factors beside the NLS motifs might regulate its 
nuclear localization. To investigate whether the nuclear localization of FANCE depends on 
other FA proteins, we looked at the nuclear expression of FANCE in different FA 
complementation groups (Fig. 4A). Nuclear FANCE was present in lymphoblastoid cell lines 
from FA complementation groups B, D2, G, I, L and M, although slightly reduced in FA-G, -I, -
L and -M cells, but was absent in nuclear extracts of cell lines from groups FA-C (EUFA1233) 
and FA-E (EUFA410). The transfection of FANCC in the FA-C cell line restored the nuclear 
expression of FANCE to wild-type levels (Fig. 5A). We further examined the effect of FANCC 
on the subcellular localization of FANCE in three other independent FA-C cell lines (GM4510, 
EUFA166 and HSC536). The expression level of FANCE in the nucleus was variable between 
cell lines, but consistently low compared to wild-type cells (Fig. 5B). Surprisingly, the FANCC 
mutant L554P present in cell line HSC536 seems to retain a substantial fraction of FANCE in 
the cytoplasm. The presence of cytoplasmic FANCE in both nuclear and cytoplasmic extracts of 
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the FA-C cells HSC536 does not interfere with the interpretation of these results (Fig. 5B). 
Taken together, these immunoblot analyses suggest that FANCC is important for proper nuclear 
accumulation and/or stability of FANCE.   
Reciprocally, the FANCC protein was not detectable in the nuclear extract of the FA-E cell 
line EUFA410, but present in the cell lines from the FA complementation groups A, B, D1, D2, 
F and G, even though FANCC appears weakly reduced in cells of complementation groups FA-
A and FA-B (Fig. 4B). Our data confirm recent studies showing that FANCE is required for the 
nuclear accumulation of FANCC [32,33] and indicate that the FANCC and FANCE proteins 
require each other in order to be stable in the nuclear compartment of the cell.   
 
 
B
EU
FA
38
8
EU
FA
12
33
EU
FA
57
9
EU
FA
12
89
EU
FA
69
8
EU
FA
14
3
CA B D1 D2 E F G
HS
C2
30
EU
FA
41
0
FANCG 
FANCA
FANCC
FANCF
A
bTUB
WT B C D2 E G L I M
HS
C9
3
EU
FA
13
86
EU
FA
12
33
EU
FA
12
89
EU
FA
41
0
EU
FA
14
3
EU
FA
86
8
EU
FA
69
5
EU
FA
86
7
FANCE
TOPO I
FANCE
WT B C D2 E G LI M
NE
WCE
 
 
Figure 4.  Expression of FANCC and FANCE proteins in nuclear extracts of FA cells derived from different 
complementation groups. (A) Nuclear localization of FANCE in wild-type lymphoblasts (HSC93) and 
lymphoblastoid cell lines from FA complementation groups B, C, D2, E, G, I, L and M. The same amount of 
nuclear protein (20 mg) was immunoblotted with a FANCE antibody. Topoisomerase I (TOPO I) and b-
tubulin (bTUB) antibodies were used as nuclear and cytoplasmic markers, respectively. In the lower part of 
the figure FANCE levels in whole cell extracts (WCE) of 500,000 lymphoblastoid cells is shown. (B) 
Nuclear localization of FANCC in wild type lymphoblasts (HSC93) and lymphoblastoid cell lines from FA 
complementation groups B, C, D1, D2, E, F and G. Equal amounts of nuclear protein (20 mg) were 
immunoblotted with anti-FANCA, anti-FANCC, anti-FANCF or anti-FANCG, as indicated.  
 
 
 
4. The nuclear translocation of FANCE is partially dependent on FANCC 
 
Because FANCC seems important for the nuclear accumulation and stability of FANCE, we 
examined the subcellular localization of transiently transfected FANCEmNLS1-2 in primary 
fibroblasts deficient in FANCC (EUFA1233). The localization of the FANCE-GFP protein was 
restricted to the nucleus of the wild-type and the FA-C fibroblasts (Fig. 6A), as observed in 
HeLa cells (Fig. 3A). Intriguingly, the mutant NLS1-2 FANCE-GFP protein was not able to 
accumulate in the nucleus of the FA-C fibroblasts, while in wild-type fibroblasts, 
FANCEmNLS1-2 showed a predominant nuclear staining with a faint cytoplasmic distribution 
(Fig. 6B). These results suggest that the nuclear translocation of FANCE becomes dependent on 
FANCC when the NLS motifs in FANCE are mutated.  
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Figure 6. FANCC is required for the nuclear accumulation of the FANCEmNLS1-2 protein. Localization 
of FANCE-GFP (panel A) and FANCEmNLS1-2-GFP (panel B) protein transiently transfected in wild-
type fibroblasts (WT) and FA-C fibroblasts (EUFA1233). Counterstaining with Hoechst is performed to 
visualise the nuclei. Magnification 400x. 
 
Figure 5. Effect of FANCC on the 
nuclear localization of FANCE. (A) 
FANCC is required for the nuclear 
accumulation of FANCE. Equal 
amounts of cytoplasmic (C) and nuclear 
(N) protein from wild-type 
lymphoblasts (HSC93), FA-C 
lymphoblasts (EUFA1233) and FA-C 
lymphoblasts stably transfected with 
FANCC-flag (EUFA1233 + FANCC) 
were immunoblotted with a FANCE 
antibody. (B) FANCE subcellular 
localization in three additional FA-C 
lymphoblastoid cell lines. Equal 
amounts of cytoplasmic (C) and nuclear 
(N) protein from the indicated 
lymphoblastoid cell lines were 
immunoblotted with FANCE antiserum. 
Topoisomerase I (TOPO I) and b-
tubulin (bTUB) antibodies were used as 
nuclear and cytoplasmic markers, 
respectively. The asterisks indicate the 
position of FANCE. 
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Figure 7. FANCEmNLS1-2 interacts with FANCC and FANCD2 in mammalian two-hybrid assays. 
Protein pairs were co-transfected in 293 cells in the presence of a luciferase reporter construct to test for 
direct interactions. (A) Interaction between FANCEmNLS1-2 and FANCC. (B) Interaction between 
FANCEmNLS1-2 and FANCD2. Fold induction is expressed relative to the luciferase activity obtained 
with the pVP16-AD-FANCC or pM-BD-FANCD2 vector alone. Results shown are mean ± S.D. and 
derived from an experiment in triplicate.    
 
 
 
 
5. FANCE has different interaction domains for FANCC and FANCD2  
 
The direct binding partners of FANCE are the FANCC and FANCD2 proteins [33-35]. To 
investigate the nature of these associations, we mapped contact sites implicated in the binding 
of FANCE by using the mammalian two-hybrid (M2H) assay. We first looked whether the 
NLS1-2 motifs in FANCE are involved in a direct interaction with either FANCC or FANCD2. 
Like wild-type FANCE, the FANCEmNLS1-2 protein showed a strong induction of the reporter 
gene with both FANCC and FANCD2 proteins (Fig. 7A and B), an indication that the NLS 
motifs are not directly involved in FANCC or FANCD2 interaction. Then, five FANCE 
deletion constructs were tested for interaction with wild-type FANCC and FANCD2 (Fig. 8). 
We found that only two FANCE fragments were able to interact with FANCC: an internal 
fragment of FANCE including the amino acids 149-371, and a fragment that lacks the first 148 
amino acids of FANCE (149-536), although the reporter gene induction was weak for the latest 
(Fig. 8A and B). The FANCD2 protein interacted only with the FANCE fragment lacking the 
N-terminus (149-536) (Fig. 8C and D). Surprisingly, this interaction produced a very strong 
induction of the reporter gene, which was stronger than the association between FANCD2 and 
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wild-type FANCE. This study suggests that the FANCE domains that interact with FANCC are 
different from the ones that interact with FANCD2 and that the N-terminus of FANCE might 
interfere with the binding of FANCD2. 
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Figure  8. Mapping binding sites for the interactions of FANCE with FANCC and FANCD2. Mammalian 
two-hybrid assays illustrating the mapping of binding sites for the interaction between FANCE and 
FANCC (A and B) and the interaction between FANCE and FANCD2 (C and D). Fold induction is 
expressed relative to the luciferase activity obtained with either the pVP16-AD-FANCC vector alone or 
the pM-BD-FANCD2 vector. Results shown are mean ± S.D. and derived from an experiment in triplicate. 
(E) Schematic representation of the FANCE fragments tested in the mammalian two-hybrid assay. The 
activity of the reporter gene between the paired constructs is indicated as (++++) very strong, (++) strong, 
(+) weak, and (-) absent. The gray boxes represent the nuclear localization signal (NLS) in FANCE. 
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DISCUSSION 
 
The FANCE protein is an essential component of the nuclear FA core complex, which directly 
links this multisubunit complex to the downstream FA protein FANCD2. In the present study 
we investigated the regulation of the nuclear accumulation of FANCE and the binding sites of 
FANCE with FANCC and FANCD2. We found that FANCE has a strong tendency to localize 
in the nucleus, since the addition of a nuclear export signal does not interfere with the nuclear 
localization of FANCE. We also demonstrate that the nuclear accumulation of FANCE is not 
only dependent on its nuclear localization signals, but also depends on FANCC, and not on 
other FA proteins. Our data support previous studies showing that FANCE is required for the 
nuclear accumulation of FANCC and protection against chromosomal breakage [32,33]. These 
results imply that FANCC and FANCE are mutually dependent on each other in the FA 
pathway. We also show that different regions in FANCE seem to mediate the direct interactions 
with FANCC and FANCD2. 
 
FANCE has been described as a nuclear protein [33]. In this study we show that it is very 
difficult to interfere with the nuclear localization of FANCE. The addition of a nuclear export 
signal to the C-terminus of FANCE does not inactivate the FANCE protein and only leads to a 
complete cytoplasmic localization of FANCE when the nuclear export receptor CRM1 is 
coexpressed. This might indicate that FANCE has a strong affinity for nuclear components, 
such as DNA or other nuclear proteins. In a recent study, Wang et al [22] showed that FANCE 
colocalizes with FANCD1/BRCA2 in chromatin, which could explain the strong tendency of 
FANCE to localize in the nucleus. Alternatively, the unidentified FANCI protein could play a 
role here (see discussion below). 
 
The FANCE protein has two putative nuclear localization signals (NLS) [9] and we tested if 
these NLS motifs are involved in the nuclear accumulation of FANCE. Surprisingly, mutation 
of both NLS motifs did not prevent the FANCE protein from entering the nucleus of wild type 
cells, suggesting that other factors are involved in the nuclear accumulation of FANCE. By 
transfection experiments in FANCC deficient fibroblasts, we demonstrated that in the absence 
of functional NLS sequences the nuclear accumulation of FANCE becomes dependent on 
FANCC. Similarly, the endogenous FANCE protein was not detected in nuclear extracts of FA-
C cells lacking FANCC, but was present in FA cells from other complementation groups. 
Lesser expression level of nuclear FANCE found in the FA-G, -L, -I and -M cells may suggests 
that these proteins confer via indirect associations optimal stabilization of FANCE in the 
nucleus. To our knowledge, the present study is the first to show that the nuclear accumulation 
of FANCE depends on FANCC, and not on other FA proteins. The variability in the expression 
levels and cellular localization of FANCE in the four FA-C cell lines tested might be related to 
the type of mutations in FANCC. In the null FA-C cell line EUFA1233 the FANCE protein was 
undetectable in both cytoplasmic and nuclear compartments (Fig. 4A and 5A). The increase of 
the nuclear expression levels of FANCE (to wild-type levels) after the reintroduction of full 
length FANCC (Fig. 5A) suggests that FANCC is crucial for the nuclear accumulation of 
FANCE. The FANCE protein was detected in the nuclear extract as well as in the cytoplasmic 
fraction of the FA-C cell line HSC536. The molecular basis of the retention of FANCE in the 
cytoplasm of the HSC536 cells is unknown. This cell line expresses the FANCC mutant L554P 
exclusively in the cytoplasmic compartment [44,45], but the L554P mutant has been shown to 
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be defective in binding FANCE using two hybrid assays [33,35]. One possible explanation is 
that FANCE weakly binds the L554P mutant in the presence of other FA proteins, which 
partially stabilizes and retains FANCE in the cytoplasmic compartment. This is consistent with 
the presence of a normal FANCA/FANCG complex in both cellular compartments of HSC536 
cells [31] and the observation that FANCE has weak and/or transient interactions with both 
FANCA and FANCG [34]. It seems unlikely that the truncated FANCC mutants of the FA-C 
cell lines EUFA166 (322delG) and GM4510 (IVS4+4A®T) [46] were able to bind to FANCE, 
since FANCC deletion constructs failed to interact with FANCE [35]. In the nuclear extracts of 
those two FA-C cell lines, the level of FANCE was markedly reduced and FANCE was not 
retained in the cytoplasmic fraction (Fig. 5B). Taken together, these results indicate that 
FANCC is important for the nuclear accumulation and/or stability of FANCE. Reciprocally, 
previous studies demonstrated that FANCC needs the FANCE protein to accumulate in the 
nucleus of the cell [32,33], which we confirmed for the endogenous FANCC protein. Other FA 
core complex members, such as FANCA and FANCB might also produce a stabilizing effect on 
FANCC in the nucleus, since nuclear FANCC levels appeared to be slightly reduced in FA-A 
and -B cells. Similarly, lower FANCE expression levels were found in the nucleus of FA-G, -I, 
-L and -M cells, suggesting that several proteins are needed for stabilization of FANCE in the 
nucleus. Surprisingly, in FA-I cells cellular FANCE levels were normal, while nuclear FANCE 
levels were reduced. Interestingly, we also found reduced nuclear FANCC and FANCD2 levels 
in FA-I cells (de Winter, unpublished results). This could indicate that the unidentified FANCI 
protein is involved in the nuclear retention of FANCC, FANCE and FANCD2.   
 
The expression of FANCC is regulated during the cell cycle and seems to involve 
proteosomal degradation [47]. We hypothesize that the FANCC/FANCE interaction occurs in 
the nucleus upon a cell cycle regulated nuclear translocation of FANCC. In the absence of 
FANCC, the nuclear FANCE protein is unstable and similarly, FANCC needs to be stabilized in 
the nucleus by binding to FANCE. Inactivation of the NLS motifs in FANCE makes the nuclear 
translocation of FANCE dependent on the interaction with FANCC (piggy bag riding) and 
expression of a FANCC mutant defective in nuclear accumulation (like in HSC536) is able to 
retain a proportion of FANCE in the cytoplasm.  
 
Does FANCE bind FANCD2 alone or in complex with FANCC? Although our study does 
not distinguish between these possibilities, the mammalian two hybrid experiments suggest that 
different FANCE fragments interact with FANCC and FANCD2 (Fig. 8). The FANCC protein 
appears to interact with an internal region of FANCE (149-371), which includes the NLS motifs 
(see also Ref. [35]), but the interaction with full length FANCE is much stronger. FANCD2 
interacts with the FANCE fragment lacking the first 148 amino acids (149-536) and all the 
other FANCE fragments failed to interact with FANCD2. This interaction is much stronger than 
with the full length FANCE, indicating that the N-terminus of FANCE might interfere with the 
binding of FANCD2. Possibly, the conformation of FANCE changes upon binding of FANCC 
and other FA proteins, thereby exposing the FANCD2 binding site. Further experiments need to 
be performed to prove this hypothesis, as we cannot exclude that removing the N-terminus of 
FANCE results in a more favorable positioning of the VP16 activation domain (AD) with 
regard to the GAL4 DNA-binding domain (BD) fused to FANCD2.  In a recent study using the 
yeast two hybrid assay three FANCE mutants (Q312X, E263K and L348M) have been 
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described that had lost their ability to bind FANCD2, but were still able to bind FANCC [48]. 
This strengthens the idea that the FANCC and FANCD2 binding sites of FANCE are different. 
 
Based on this and previous studies, we propose a model for the sequential assembly of the 
nuclear FA core complex. The cytoplasmic FANCA/FANCG [41,49] and FANCB/FANCL [13] 
subcomplexes are probably translocated to the nucleus independently. In the nucleus these 
complexes interact, which needs the recently identified FANCM protein. The FANCE protein 
directly interacts with FANCC in the nucleus and then associates with the 
FANCA/FANCB/FANCG/FANCL subcomplex, an interaction that is stabilized by FANCF 
[31,40]. The association of the nuclear FA core complex with other factors (e.g. FANCI [16]) or 
the association of the FANCC/FANCE subcomplex with FANCF [40] could induce a structural 
change in FANCE resulting in the binding and monoubiquitination of FANCD2. It is also 
possible that posttranslational modifications of FANCD2 during S-phase (e.g. phosphorylation) 
permit the FANCE/FANCD2 interaction to occur.     
 
We conclude that the FANCC and FANCE proteins are functionally linked since they require 
each other to be stable in the nucleus of the cell. FANCC is important for the nuclear 
accumulation and/or stability of FANCE and similarly, FANCE is essential for the function of 
FANCC in the nucleus. Relationships between the FA proteins inside the FA core complex 
emerge as a complicated network of protein-protein interactions where FANCC and FANCE 
are tightly interrelated. A similar relationship has been found for the FANCA/FANCG and 
FANCB/FANCL protein pairs.  
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THE FANCONI ANEMIA (FA) protein FANCF is an essential component of a nuclear core 
complex that functions to protect the genome against chromosomal instability, but the specific 
function of FANCF is still poorly understood. Based upon the homology between human and 
Xenopus laevis FANCF, we carried out a mutagenesis study to clarify which domains are 
functionally important and to gain insight into the function of FANCF. In contrast to previous 
suggestions, we show that FANCF does not have a ROM-like function. We found that the C-
terminus of FANCF interacts directly with FANCG and allows the assembly of other FA 
proteins into a stable complex. The N-terminus appears to stabilize the interaction with FANCA 
and FANCG, and is essential for the binding of the FANCC/FANCE subcomplex. We 
identified several important amino acids in this N-terminal region but, surprisingly, many amino 
acid changes failed to affect the function of the FANCF protein. Our data demonstrate that 
FANCF acts as a flexible adaptor protein that plays a key role in the proper assembly of the FA 
core complex. 
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INTRODUCTION 
 
Fanconi anemia (FA) is an autosomal recessive chromosomal instability syndrome. The clinical 
phenotype of FA patients is characterized by congenital abnormalities, progressive bone 
marrow failure, and a predisposition to cancer; particularly acute myeloid leukemia and 
squamous cell carcinoma (1,2). The spontaneous cytogenetic aberrations specific for FA cells 
are exacerbated upon treatment with DNA cross-linking agents, such as mitomycin C (MMC) 
and diepoxybutane, which suggests a DNA maintenance defect particularly in the handling of 
cross-link damage.  
 
To date, somatic cell fusion studies have demonstrated 11 FA complementation groups (A-C, 
D1, D2, E-G, I, J, L) (3) and eight of the FA associated genes have been identified: FANCA, 
FANCC, FANCD1/BRCA2, FANCD2, FANCE, FANCF, FANCG and FANCL (4-12). These FA 
genes encode orphan proteins and no functional domains have been found in their primary 
amino acid sequences, except for a RING finger in FANCL (10) and multiple TPR motifs in 
FANCG (13). In FANCF a region with homology to RNA-binding protein ROM has been 
suggested to provide a clue for its function (5). 
 
FANCA, FANCC, FANCE, FANCF, FANCG and FANCL assemble in a nuclear core 
complex (10, 14-17), in which FANCG binds directly to FANCA and FANCF and FANCC 
binds to FANCE (15, 16). The FA core complex is essential for the monoubiquitination of 
FANCD2  (18) and this modified form of FANCD2 colocalizes with BRCA1, RAD51 (19) and 
PCNA (20) in foci that also contain other DNA repair proteins. Nevertheless, it is still unknown 
how monoubiquitinated FANCD2 is involved in DNA repair and MMC resistance. Recently, 
biallelic mutations in BRCA2 have been found in cell lines derived from FA-D1 patients, 
adding BRCA2 to the list of FA proteins (8). The BRCA proteins are known to be involved in a 
multitude of biological functions including DNA repair, recombination, cell cycle control and 
transcription (21). BRCA2 appears to be directly linked to the repair of double-stranded breaks 
(DSBs) by homologous recombination (22). FANCD2 has also been identified as a target of the 
ataxia telangiectasia (AT) signaling pathway (23) and seems to be functionally connected to the 
RAD50/MRE11/NBS1 (RMN) protein complex (24, 25), which plays an important role in the 
repair of DSBs (26). Taken together, these data suggest that the FA proteins serve to maintain 
genomic stability and integrity, in concert with other protein complexes.  
 
FANCF plays an important role in the FA pathway and its functional disruption seems to be 
involved in specific types of cancer, as suggested from the hypermethylation of the FANCF 
promoter in a subset of ovarian, oral, lung and cervical cancers (27, 28, 29). Nevertheless, the 
function of FANCF is poorly understood. Patient-derived mutant forms of FA proteins and 
structure/function analysis of FANCA, FANCC and FANCG have been informative in finding 
important functional residues (30-34), but for FANCF this information is lacking, since none of 
the FA-F patients have missense mutations that could provide insight into its function (5). For 
this reason, we started a site-directed mutagenesis study to obtain more information about 
functional domains in the FANCF protein. Because such domains are expected to be relatively 
conserved during evolution, we searched for FANCF homologs in lower vertebrates that might 
highlight important residues in FANCF. We found a Xenopus laevis homolog of FANCF 
(xFANCF), which has a relatively low overall homology with human FANCF. However, two 
76     Chapter 5                                                                           
 
 
relatively conserved regions were located at the N- and C- terminus. Based upon this 
conservation and amino acid properties, we generated FANCF a large panel of FANCF mutants 
and identified several functionally important amino acids and domains in FANCF. This study 
reveals that FANCF is an adaptor protein that plays a key role in the proper assembly of the FA 
core complex. To be able to perform this function the N-terminus of FANCF interacts with the 
FANCC/FANCE subcomplex, whereas the C-terminus binds to the FANCA/FANCG 
subcomplex.  
 
 
EXPERIMENTAL PROCEDURES 
 
Cell Culture and Transfection 
Epstein-Barr virus (EBV)-transformed lymphoblasts were cultured in RPMI 1640 media 
supplemented with 1 mM glutamine (Gibco, Invitrogen, Carlsbad, CA, USA) and 10% fetal calf 
serum (FCS; Gibco). Selection medium to obtain stable cell lines also contained hygromycin B 
(100 µg/ml; Roche, Basel, Switzerland). For stable expression lymphoblastoid cell lines were 
transfected by electroporation using an ECM830 electro square porator (BTX, San Diego, CA, 
USA). The MMC-induced growth inhibition assays were performed as previously described 
(35-36).  
 
Generation of FANCF Mutant Constructs 
The FANCF mutant constructs were generated by polymerase chain reaction (PCR) with 
oligonucleotides encoding the amino acid substitutions or deleted regions of the FANCF 
sequence. We used as a template the FANCF cDNA clone 10 obtained by expression cloning 
(5). The FANCF mutant R47A+F48A was made using the QuikChange site-directed 
mutagenesis kit (Stratagene, La Jolla, CA, USA) according to the manufacturer’s instructions. 
All FANCF mutants have been analyzed by sequencing to confirm that the desired changes had 
occurred and to exclude the presence of other PCR derived alterations. The mutants were 
subcloned into the expression vector pCEP4 (Invitrogen) and transfected in FA-F lymphoblasts, 
EUFA698. FANCF mutants 1-15del and delC31, and wild type FANCF-Flag were also 
subcloned into the expression vector pIRESneo (Clontech, Palo Alto, CA, USA) to generate 
stable cell lines. Expression of the mutant proteins in the stable cell lines was confirmed by 
immunoprecipitation and immunoblotting with FANCF-specific antibodies.  
 
Sequence Analysis 
FANCF mutants and the Xenopus laevis FANCF IMAGE clone 3200942 (obtained from 
HGMP Resource Centre, Cambridge, UK), were subcloned in pBluescript SK- and were 
sequenced with CY5.5 labeled T7 and T3 primers using a Thermo Sequenase primer cycle 
sequencing kit (Amersham). Products were analysed on a Visible Genetics automatic DNA 
sequencer (Visible Genetics Inc, Toronto, Ontario, Canada). 
 
Yeast Two-hybrid Analysis 
The MATCHMAKER Two-Hybrid System 3 (Clontech) was used according to the 
manufacturer’s instructions as previously described (15). In brief, bait and prey constructs were 
sequentially transformed into AH109 yeast cells and selected on -Trp-Leu-His-Ade medium. 
The resulting colonies were tested for b- galactosidase expression with 5-bromo-4-chloro-3-
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indolyl-b-D-galactopyranoside (X-gal). To confirm interactions a yeast-mating assay was used 
where constructs were transformed separately into two different yeast strains and mating 
cultures plated onto selection medium as above. All constructs were tested for self-activation 
against a series of control plasmids and expression of the mutant proteins was verified by 
immunoblotting. 
 
Mammalian Two- and Three-hybrid Analysis 
Human embryonic kidney cells 293, either untransfected or stably transfected with wild type or 
mutant (L554P) FANCC were plated onto six well plates. After 48h, the cells were transiently 
transfected with FANCE cDNA fused to the GAL-4 activation domain (pVP16; Clontech) and 
the indicated FANCF constructs fused in frame to the GAL4 DNA-binding domain (pM; 
Clontech) (1 mg of each), together with a GAL4 driven reporter plasmid (G5E1bLUC, 0.2 mg). 
The luciferase activity was monitored after 24 h using a Dual-Luciferase Reporter Assay 
System (Promega) and a single tube luminometer (DLReady, Berthold Detection Systems), 
according to the manufacturer’s instructions. All GAL4 constructs were sequenced to confirm 
the correct reading frame and each experimental data set was performed in triplicate to 
overcome the variability inherent to transfections. Transient expression of the FANCF 
constructs and stable expression of FANCC were confirmed by immunoblotting with FANCF 
and FANCC specific antisera.  
 
Subcellular Fractionation, Immunoprecipitation and Immunoblotting 
Nuclear and cytoplasmic fractions of the lymphoblastoid cell lines were obtained as described 
previously (17). Cell extracts (~107 cells) were prepared in lysis buffer (50 mM Tris pH 7.4, 
150 mM NaCl and 1% Nonidet NP40 supplemented with protease inhibitors) and subjected to 
immunoprecipitation using the indicated antibodies, as previously described (14). Anti-FLAG 
M2 affinity gel (Sigma-Aldrich, Saint-Louis, MO, USA) was used to immunoprecipitate 
FLAG-tagged proteins. Immunoprecipitates or lysates were then separated on 8 % SDS-
polyacrylamide gels, transferred to PVDF membranes and specific proteins were detected by 
immunoblotting with the indicated antibodies.  
 
 
 
RESULTS 
 
Homology between the Human and Xenopus FANCF Proteins 
 
Since functionally important amino acids are well conserved between species, we searched 
several databases for FANCF homologs to obtain clues about functional domains. In the NCBI 
database an IMAGE clone (3200942) was found, which represents the full-length Xenopus 
laevis homolog of FANCF (xFANCF). The cDNA was sequenced and the predicted protein was 
aligned with the human FANCF sequence (Fig. 1). The overall homology between both 
sequences appeared to be limited (27% identity, 49% similarity) and dispersed over the whole 
molecule. However, relatively high sequence conservation was found in both the N- and C-
terminal regions of the protein. To test if this limited homology was sufficient to function in a 
human background, FLAG-tagged xFANCF was transfected into a cell line from an FA-F 
patient (EUFA698). Unlike the human protein, xFANCF was unable to complement the MMC 
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hypersensitivity of the cells, despite of its proper expression (Fig. 2). The untagged xFANCF 
protein was also unable to complement the MMC defect in FA-F cells (data not shown), 
indicating that xFANCF is not able to restore the human FA pathway.  
 
 
F1-15del
hFANCF 1 MESLLQHLDRFSELLAVSSTTYVSTWDPATVRRALQWARYLRHIHRRFGRHGPIRTALER
xFANCF 1 MHTMLENLDRFIELLTLSQSVHVKDWDILCVRRGFEWGSYFQQVYHRFCANDCLRNALED
hFANCF 61 RLHNQWRQEGGFGRGPVPGLANFQALGHCDVLLSLRLLENRALGDAARYHLVQQLFPGPG
xFANCF 61 HLRSKNQKLSTCIKN--YQYISFNDLRHSKDIFCTSLLQNKALSRNIFQYIVTKLK----
hFANCF 121 VRDADE ETLQESLARLARRRSAVHMLRFNGYRENPNLQEDSLMKTQAELLLERLQ-EVGK
xFANCF 115 -NQSSGETNTCNMSNIMCQKAASALLLFPSSIDSKNPLENPCAVTEAEILKNHLEYRIHS
*      *
hFANCF 180 AEA ERPARFLSSLWERLPQNNFLKVIAVALLQPPLSRRPQEELEPGIHKSPGEG SQVLVH
xFANCF 174 LKE DHQFAVVSDVLSGIPQPSIYNLLAILLLSSETCD-SQDQLS---------LSHLLLK
hFANCF 240 WLLGNSEVFAAFCRALPAGLLTLVTSRHPALSPVYLGLLTDWGQRLHYDLQKGIWVGTES
xFANCF 224 WLLENDSVWTDFCSKIHSHLLSHLSSKYSIVRKAYFNFLIKLGESMELDVQG-KWVSN-S
hFANCF 300 Q DVPWEELHNRFQSLCQAPPPLKDKVLTALETCKAQDGDFEVPGLSIWTDLLLALRSGAF
xFANCF 282 A ELSFDIFLNHFESLMKTSEDLQTATEATLEDLKRQDGDYNVPGISVWTDVLLEVKRI
hFANCF 360 RKRQVLGLSAGLSSV            FdelC40      FdelC31    FdelC23  
 
Figure 1. Sequence alignment of human and Xenopus laevis FANCF proteins. Alignments were made with 
BoxShade. The black-shaded residues are identical and the gray-shaded residues are similar between human 
and Xenopus FANCF. The box shows the region homologous to the prokaryotic RNA-binding protein ROM.  
The asterisks point out the amino acids essential for RNA-binding activity in ROM and the triangles indicate 
the amino acids that were mutated in the ROM homologous region. The N- and C-terminal deletion mutants 
that were generated are also indicated. GenBankTM accession number for xFANCF: AY547288. 
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Figure 2. Xenopus FANCF protein is not functional in human cells. (A) MMC hypersensitive phenotype of 
the FA-F lymphoblastoid cell line EUFA698 is corrected by stable transfection with cDNA encoding human 
FANCF, but not with cDNA encoding Xenopus FANCF. (B) Expression of FLAG-tagged human and 
Xenopus FANCF proteins in EUFA698 cells. Cell lysates of the indicated cell lines were immunoprecipitated 
with anti-FLAG antibody and immunoblotted with rabbit FANCA antiserum 89 and anti-FLAG.   
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The FANCF Region Homologous to ROM Is Not Conserved and Not Essential for Function 
 
FANCF was first described as a novel protein with homology to the prokaryotic RNA-binding 
protein ROM (5). The sequence alignment shows that the FANCF region homologous to ROM 
(amino acids 145-209) is not well conserved between human and Xenopus FANCF. 
Furthermore, the amino acids essential for RNA binding (Gln-166 and Arg-173) are not 
identical in xFANCF. To further study this region, Arg-173 was changed into alanine and the 
mutant protein was tested for its ability to complement the MMC hypersensitivity of FA-F cells. 
Although this amino acid change abolished RNA binding in ROM (37), it did not have an effect 
on the activity of FANCF (Fig. 3). Similarly, FANCF mutants of the glutamic acid that is 
identical between hFANCF and ROM (E172A and E172P) were still functional. These data 
suggest that the FANCF region homologous to ROM is unlikely to have an essential ROM-like 
function. 
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Figure 3.  The FANCF region homologous to ROM is not required to correct the MMC hypersensitivity of 
FA-F cells.  Sequence alignment showing the homology between human FANCF and the prokaryotic RNA-
binding protein ROM. The asterisks point out the amino acids essential for RNA-binding activity in ROM 
and the triangles indicate the amino acids that were mutated. The MMC hypersensitive phenotype of the FA-
F lymphoblastoid cell line EUFA698 is corrected to wild type levels by stable transfection with cDNAs 
encoding the FANCF mutants R173A, E172A and E172P. Lymphoblastoid cell line HSC93 is shown as a 
wild-type control.  
 
 
 
The C-terminus of FANCF Binds Directly to FANCG 
 
Relatively high sequence conservation was found in the C-terminus of FANCF (Fig. 1). To 
study the function of this conserved region, several deletion constructs were generated and 
tested for their ability to complement the MMC hypersensitive phenotype of FA-F cells. 
Surprisingly, FANCF mutants with C-terminal deletions of 23, 31, or 40 amino acids all 
80     Chapter 5                                                                           
 
 
complemented the MMC hypersensitivity of FA-F cells (Fig. 4A), although the survival curves 
were slightly shifted towards a higher sensitivity when more amino acids were deleted. 
Consistent with the notion that FANCD2 monoubiquitination is required for MMC resistance, 
FA-F cells transfected with the delC31 mutant expressed monoubiquitinated FANCD2 under 
normal conditions and after MMC treatment (data not shown). Co-immunoprecipitation 
experiments showed that the FANCF deletion mutants had a reduced interaction with FANCA 
and FANCG when compared to wild type FANCF (Fig. 4B). Deletion of 31 or 40 amino acids 
completely abolished the interaction in this assay. Since FANCF has been shown to interact 
directly with FANCG (15, 38), we tested the interaction between FANCG and the deletion 
mutants in a yeast two-hybrid assay. In both co-transformation and mating experiments the 
mutants with a deletion of 31 or 40 amino acids had a strongly reduced FANCG binding (Table 
I). These results demonstrate that the last 31-40 amino acids in the C-terminus of FANCF are 
important for the direct interaction with FANCG. By interfering with the binding to FANCG, 
the interaction with FANCA is also disturbed, indicating that the C-terminus of FANCF is 
binding the FANCA/FANCG subcomplex through FANCG. 
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Figure 4. Deletion mutants of the C-terminus of FANCF are functional, but do not stably interact with 
FANCA and FANCG. (A) MMC hypersensitive phenotype of the FA-F cell line EUFA698 is corrected after 
stable transfection with FANCF mutants that lack 23 (FdelC23), 31 (FdelC31) or 40 (FdelC40) amino acids 
of the C-terminus. Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Cell lysates from 
wild-type (HSC93), FA-F (EUFA698) and the indicated stably transfected FA-F lymphoblasts were 
immunoprecipitated with guinea pig anti-FANCF1-245 and immunoblotted with rabbit FANCA antiserum 89, 
rabbit anti-FANCG83-622 and rabbit anti-FANCF1-374 to show precipitated FANCA, FANCG and FANCF. The 
asterisks indicate the position of FANCG. 
 
 
 
The N-terminus of FANCF Is Involved in Binding of the FANCC/FANCE Subcomplex 
 
We next evaluated the function of a deletion mutant of FANCF that lacked the highly conserved 
first 15 amino acids of FANCF. The mutant FANCF protein was not able to complement the 
MMC hypersensitivity of FA-F cells, despite its proper expression and nuclear localization (Fig. 
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5). Although this mutant protein interacted with FANCA and FANCG, the interaction was weak 
compared to that of wild type FANCF (Figs. 4B and 8B).  
 
 
 
TABLE I 
 Yeast two-hybrid data of FANCG and the C-terminal deletion mutants of FANCF 
 DNA-BD: pGBK-FANCG  
DNA-AD: pGAD-FANCF-delC 
Reporter gene 
activation 
FANCF-delC23 +++ 
FANCF-delC31 + 
Co-transformations 1 and 2 
FANCF-delC40 + 
FANCF-delC23 +++ 
FANCF-delC31 + 
Mating assays 1 and 2 
FANCF-delC40 - 
 BD, GAL4 binding-domain. AD, GAL4 activation-domain. 
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Figure 5. Deletion of amino acids 1 to 15 inactivates FANCF, without affecting the nuclear localization. (A) 
MMC hypersensitive phenotype of the FA-F cell line EUFA698 is not corrected after stable transfection of 
cDNA encoding a FANCF mutant from which the first N-terminal 15 amino acids were deleted (F1-15del). 
Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Subcellular localization of FANCF 
mutant F1-15del. Equal amounts of cytoplasmic (C) and nuclear (N) proteins from wild-type (HSC93), FA-F 
(EUFA698) lymphoblasts and EUFA698 stably transfected with FANCF mutant F1-15del (EUFA698 + F1-
15del) were immunoprecipitated with anti-FANCF1-245. Precipitated FANCF was visualized by 
immunoblotting with rabbit anti-FANCF1-374. Topoisomerase II b (TOP2b) and b-tubulin (bTUB) antibodies 
were used as nuclear and cytoplasmic markers, respectively. 
 
 
 
82     Chapter 5                                                                           
 
 
Unlike wild-type FANCF, which can be immunoprecipitated in a complex with FANCE, we 
did not detect any FANCE in a complex with the N-terminal deletion mutant of FANCF with 
antisera against FANCE (Fig. 6A). Furthermore, the mutant did not restore the interaction 
among FANCE, FANCA and FANCG that is observed in wild-type cells. Similarly, the C-
terminal deletion mutant lacking the last 31 amino acids was also unable to bind FANCE and 
could not form a stable FA complex (Fig. 6A). In a reciprocal experiment, FANCC and FANCE 
did not co-immunoprecipitate with the N-terminal deletion mutant (Fig. 6B). Taken together, 
these results indicate that the N-terminus of FANCF is essential for its function and is involved 
in binding of FANCC and FANCE.  
 
An important question for functional studies is how these proteins associate in the core 
complex. Previously, no direct interaction between FANCF and FANCC or FANCE has been 
found in yeast two-hybrid assays (15, 38), suggesting that the association with FANCC and 
FANCE is indirect. We investigated these interactions in a mammalian two-hybrid assay and 
also in this assay FANCF did not interact with FANCC or FANCE (Fig. 6C), whereas an 
interaction between FANCC and FANCE was observed. We then sought to determine if the N-
terminus of FANCF might be involved in the binding of this FANCC/FANCE subcomplex, 
using a mammalian three-hybrid (M3H) system, with 293 cells stably overexpressing FANCC. 
In this assay, we observed a strong induction of the reporter gene when FANCF was 
cotransfected with FANCE (Fig. 6D), indicating that FANCC acts as a molecular bridge 
between FANCF and FANCE. As a control experiment, we used a 293 cell line stably 
overexpressing FANCC mutant L554P, which is defective in binding FANCE (16, 38) and 
found no interaction between FANCF and FANCE (data not shown). To further extend these 
observations, we tested the FANCF N- and C-terminal deletion mutants in the M3H assay. In 
agreement with our co-immunoprecipitation experiments, the FANCF mutant 1-15del 
completely failed to interact with FANCE, whereas the FANCF mutant delC31 had a reduced 
interaction (Fig. 6D). Collectively, these observations indicate that the first 15 amino acids of 
FANCF are essential for the direct binding of the FANCC/FANCE subcomplex. Furthermore, 
they demonstrate that this interaction also partially depends on the C-terminal part of the 
FANCF protein.  
 
 
The N-terminus of FANCF Contains Several Residues Essential for Its Function 
 
Several missense mutants were generated to delineate amino acids in the N-terminal region of 
FANCF essential for its interaction with other FA proteins and for its ability to complement the 
MMC defect in FA-F cells (see Table II). Secondary structure prediction programs indicate that 
the first 15 amino acids of human FANCF form an amphipathic a-helix (Fig. 7), with a strong 
negative charge at one side of the helix (Glu-2, Asp-9 and Glu-13). In the Xenopus homolog a 
similar structure was predicted, with Glu-6, Asp-9 and Glu-13 at the negative side of the helix.  
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Figure 6. Interaction of FANCF mutants with the FANCC/FANCE subcomplex. (A) Cell lysates from wild-
type (HSC93), FA-F (EUFA698) lymphoblasts and FA-F cells stably transfected with the indicated FANCF 
mutants were immunoprecipitated with anti-FANCE and immunoblotted with anti-FANCA serum 89, anti-
FANCG83-622, anti-FANCF1-374 and anti-FANCE to visualize FANCA, FANCG, FANCF and FANCE 
respectively. The asterisks indicate the position of FANCG. (B) EUFA698 cells were stably transfected with 
cDNAs encoding the FANCF mutant F1-15del-FLAG and wild-type FANCF-FLAG in expression vector 
pIRESneo. Immunoprecipitation was performed with anti-FLAG resin and immunoprecipitated FA proteins 
were visualized by immunoblotting with anti-FANCA serum 89, anti-FANCC106-558, anti-FANCE and anti-
FANCF1-374. (C) Mammalian two-hybrid assay indicating a lack of direct interaction between FANCF and 
FANCC or FANCE. Fold induction is expressed relative to the luciferase activity obtained with empty 
vectors (pM and pVP16). (D) Mammalian three-hybrid assay illustrating the interaction of FANCF and 
FANCF mutants with the FANCC/FANCE subcomplex. Fold induction is expressed relative to the luciferase 
activity obtained with the pVP16-AD-FANCE vector alone. Results shown are mean ± standard deviation 
(SD) and derived from an experiment in triplicate.  
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Figure 7. The N-terminus of FANCF contains two amphipathic a-helices. Sequence alignment showing the 
homology between the N-terminus of human and Xenopus laevis FANCF. Two amphipathic a-helices were 
predicted by Jpred and DNAsis software. The arrows indicate the hydrophobic moment of the helices. The 
functionally important amino acids are in bold and underlined. Asterisks indicate the serine-threonine stretch. 
 
 
 
 
These negatively charged amino acids were either changed into alanines (E2A+D9A+E13A) 
or replaced by positively charged lysines (E2K+D9K+E13K) and the mutants were tested for 
their ability to complement the MMC hypersensitivity of FA-F cells, and for their ability to 
interact with FANCA. Both mutants were able to complement the MMC defect (Fig. 8A), but 
like the N-terminal deletion mutant, the E2K+D9K+E13K mutant appeared to have a reduced 
interaction with FANCA (Fig. 8B). Since the C-terminus of FANCF is also involved in the 
interaction with FANCA, we tested mutants with a combination of mutation and deletions to 
determine if the N- and C- terminal conserved regions of FANCF act in concert. When the last 
23 C-terminal amino acids were removed, the E2A+D9A+E13A mutant was still biologically 
active, whereas the E2K+D9K+E13K mutant became inactive (Fig. 8C). We then removed 31 
C-terminal amino acids of these mutants and found that this completely abolished the activity of 
both mutants (Fig. 8D). Thus, reversing the charges of the residues in the FANCF a-helix is 
more disruptive than neutralizing the positively charged residues. We infer that the three 
negatively charged amino acids in the first N-terminal a-helix of FANCF are functionally 
important and that FANCF has partially interdependent functional terminal domains. 
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Figure 8. The negatively charged amino acids in the first N-terminal a-helix of FANCF have an important 
function. (A) MMC hypersensitive phenotype of the FA-F cell line EUFA698 is corrected after stable 
transfection of cDNAs encoding FANCF mutants in which the negatively charged amino acids Glu-2, Asp-9 
and Glu-13 were mutated. Lymphoblastoid cell line HSC93 is shown as a wild-type control. (B) Cell lysates 
from FA-F lymphoblasts (EUFA698) and FA-F lymphoblasts stably transfected with the indicated FANCF 
mutants were immunoprecipitated with guinea pig anti-FANCF1-245 and immunoblotted with rabbit FANCA 
antiserum 89 and rabbit anti-FANCF1-374 to show the interaction between the different FANCF mutants and 
FANCA. (C) Deletion of 23 amino acids from the FANCF mutants in which the negatively charged amino 
acids were mutated does only affect the ability of the E2K+D9K+E13K mutant to complement the MMC 
hypersensitive phenotype of the FA-F cell line EUFA698. (D) FANCF mutants in which the negatively 
charged amino acids were mutated are unable to complement the MMC hypersensitive phenotype of the FA-
F cell line EUFA698 upon removal of the C-terminal 31 amino acids.  
 
 
 
The hydrophobic side of the N-terminal a-helix contains three conserved leucines (Leu-5, 
Leu-8 and Leu-15). When these leucines were replaced by alanines, the mutant protein was 
functional in a MMC test (Fig. 9A). However, this mutant was totally inactivated upon removal 
of the 31 C-terminal amino acids (Fig. 9A), hinting that the conservation at the hydrophobic 
side of the helix is of functional significance. We then examined the ability of the FANCF 
mutant L5A+L8A+L15A (with an intact C-terminus) to interact with the FANCC/FANCE 
subcomplex in the M3H assay and found that this mutant failed to activate transcription of the 
luciferase reporter gene (Fig. 9C). These results suggest that the three leucines residues are 
involved in the direct binding of the FANCC/FANCE subcomplex.  
We further investigated N-terminal mutants, in which combinations of the conserved arginine 
(Arg-10) or phenylalanine (Phe-11) residues were modified. All the single mutants were able to 
complement the MMC hypersensitivity of FA-F cells (Table II) and displayed a normal 
86     Chapter 5                                                                           
 
 
interaction with FANCA (Fig. 8B). These mutants were still functional when the C-terminal 31 
amino acids were removed (Table II). However, a double mutant in which both Arg-10 and 
Phe-11 were changed into alanine (R10A+F11A) had a reduced biological activity, but only in 
combination with a C-terminal deletion of 31 amino acids (Fig. 9B). A possible explanation for 
the partial inactivation of the protein is the prediction of a similar a-helix (amino acids 31-48), 
in which a conserved arginine (Arg-47) and phenylalanine (Phe-48) are found (Fig. 7). These 
amino acids might be able to partially compensate for the amino acid changes in the first a-
helix. To test this hypothesis, we constructed a mutant in which the arginines and 
phenylalanines in both helices were replaced by alanines (R10A+F11A+R47A+F48A). When 
combined with a deletion of the C-terminus, this mutant was totally inactive (Fig. 9B). A mutant 
in which only Arg-47 and Phe-48 were changed (R47A+F48A) was functional (Fig. 9B). These 
results indicate that the conserved arginines (Arg-10 and Arg-47) and phenylalanines (Phe-11 
and Phe-48) in the first and second a-helix may form a functional unit. The M3H assay was 
used to show that the R10A+F11A+R47A+F48A mutant (with an intact C-terminus) was 
unable to interact with the FANCC/FANCE subcomplex (Fig. 9C), suggesting that these 
arginine and phenylalanine residues participate in this direct interaction.    
 
In order to investigate whether the two predicted N-terminal a-helices are really being 
formed and function as a unit, several leucine to proline mutants were made to disrupt the 
helical structure of this region (Table II). The disruption of the first a-helix by substitution of 
Leu-8 or Leu-14 as well as the disruption of the second a-helix by substitution of Leu-41 
interfered with the biological activity of the protein, but again only when the C-terminal 31 
amino acids were removed. As a control, we replaced Leu-14 by alanine and deleted its C-
terminus, and found that this did not affect the function of the protein. These results imply that 
the two N-terminal a-helices in FANCF form a functionally important structure, which 
cooperates with the C-terminus of the protein. 
A serine and threonine stretch (Ser-18, Ser-19, Thr-20, Thr-21) is located just after the first 
N-terminal a-helix. To investigate the functional significance of this region we changed these 
amino acids into alanines. This mutant was again inactive after removal of its C-terminus (Fig. 
9D). However, a mutant (S18A) in which only the conserved Ser-18 was changed to an alanine 
appeared to be functional (Fig. 9D). Subsequent analysis of these FANCF mutants (with an 
intact C-terminus) in the M3H assay showed that only the mutant S18A was able to activate the 
luciferase reporter gene (Fig. 9E). These data suggest that the serine and threonine stretch is of 
functional importance and is involved in the binding of the FANCC/FANCE subcomplex. 
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Figure 9. Other functional important amino acids in the N-terminus of FANCF.  (A) FANCF mutant in 
which Leu-5, Leu-8 and Leu-15 are changed into alanines is not able to complement the MMC 
hypersensitive phenotype of EUFA698 cells after removal of the C-terminal 31 amino acids. (B) Effect of 
arginine and phenylalanine-substitutions in FANCF on the ability to complement the MMC hypersensitive 
phenotype of EUFA698 cells. FANCF mutants R10A+F11A and R10A+F11A+R47A+R48A are inactivated 
upon removal of the C-terminus.  (C) Mammalian three-hybrid assay illustrating the disturbed interaction 
between the FANCF mutants 3xL (L5A+L8A+L15A) and 2xRF (R10A+F11A+R47A+R48A) and the 
FANCC/FANCE subcomplex. Results shown are mean ± S.D. and derived from an experiment in triplicate. 
Fold induction is expressed relative to the luciferase activity obtained with the pVP16-AD-FANCE vector 
alone. (D) FANCF mutant in which Ser-18, Ser19, Thr-20 and Thr-21 are changed into alanine is not able to 
complement the MMC hypersensitive phenotype of EUFA698 cells after removal of the C-terminal 31 amino 
acids. (E) Mammalian three-hybrid assay showing interaction of the FANCC/FANCE subcomplex with wild 
type FANCF and FANCF mutant S18A, which is lost in the FANCF mutant S18A-S19A-T20A-T21A 
(SSTT/A). 
 
 
 
Amino Acids 76 to 84 Are Not Essential for the Function of FANCF 
 
FA-F patient EUFA698 has a 23 bp deletion in the FANCF gene resulting in a frame shift at 
codon 77 (5). Since the deleted region is poorly conserved between human and Xenopus 
FANCF, we tried to overcome the defect by selection for a phenotypic revertant in vitro. After 
long-term culture of a lymphoblastoid cell line from patient EUFA698 in the presence of 15 nM 
MMC a MMC resistant cell line was obtained. Sequence analysis indicated that a deletion of 
nucleotide 225 (225delT) had restored the FANCF reading frame in one allele of the reverted 
88     Chapter 5                                                                           
 
 
cell line (Fig. 10). In the mutant protein, Pro-76 is changed into a glutamine while amino acids 
77 to 84 are absent. This FANCF mutant is expressed and has a normal interaction with 
FANCA (Fig. 10). These data therefore indicate that amino acids 76 to 84 are not essential for 
the complementing activity of the FANCF protein and support the idea that the structure of 
FANCF is rather flexible. 
 
 
 
TABLE II 
Activity of the FANCF mutants in different assays 
           
FANCF mutant 
 
MMC test 
 
 
FANCA 
interaction 
(IP) 
 
MMC test 
upon removal 
of the  
C-terminus 
 
FANCC/ 
FANCE 
interaction 
(M3H) 
delC31 + - na ¯ 
1-15del - ¯ nd - 
Q6A + + + nd 
D9A + R10A + nd + nd 
R10A + + + nd 
R10E + + + nd 
F11A + + + nd 
F11Y + + + nd 
R10A + F11A + + ¯ - 
F11A + E13A + + ¯ nd 
R47A + F48A + + + nd 
R10A + F11A + R47A 
+ F48A  
+ nd - - 
E2A + D9A + E13A + + - nd 
E2K + D9K + E13K + ¯ - nd 
L5A + L8A + L15A + ¯ - - 
L8P + nd - nd 
L14P + nd - nd 
L14A + + + nd 
L41P + + - nd 
L8P + L41P + nd nd nd 
L14P + L41P + nd nd nd 
S18A + + + + 
S18A + S19A + T20A 
+ T21A 
+ + - - 
Mutants in bold are not complementing MMC sensitivity. 
+, normal activity.  -, no activity. na, not applicable. ¯, reduced activity.  nd, not determined. 
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Figure 10. Amino acids 76-84 are not essential for the function of FANCF. A 23-base pair deletion (230-
252del) in FA-F patient EUFA698 results in a frameshift at codon 77 (Val-77). The FANCF reading frame is 
restored by a deletion of nucleotide 225 in revertant cell line EUFA698R, which changes Pro-76 into Gln and 
deletes amino acids 77 to 84. Cell lysates from wild type lymphoblasts (HSC93), FA-F lymphoblasts 
(EUFA698) and the reverted FA-F lymphoblasts (EUFA698R) were immunoprecipitated with guinea pig 
anti-FANCF1-245 and immunoblotted with rabbit FANCA antiserum 89 and rabbit anti-FANCF1-374 to show 
the interaction between FANCF and FANCA. 
 
 
 
 
DISCUSSION 
 
Highly conserved amino acids are generally thought to be critical for a protein’s function. By 
using an extensive site-directed mutagenesis approach we have investigated the functional 
importance of amino acids that are conserved between human and Xenopus laevis FANCF. Our 
results demonstrate that the C-terminus of FANCF binds directly to FANCG and is required for 
stable interaction with FANCA, FANCC and FANCE. Furthermore, we found that the N-
terminus of FANCF is essential for the direct interaction with the FANCC/FANCE 
subcomplex, and is important for stabilizing the complex formation with FANCA and FANCG. 
This study shows that FANCF is an adaptor protein, which keeps the other components of the 
FA core complex together in such a way that they can perform their function. 
 
A direct interaction between FANCF and FANCG has been demonstrated using the yeast 
two-hybrid system (15) and the carboxy terminus of FANCF (amino acids 243-374) was shown 
to be essential for this interaction (38). In the current study, we found that the interaction site is 
specifically located in the strongly conserved last 31 amino acids (amino acids 343-374) of 
FANCF and that this particular region provides stability to the FA core complex. Surprisingly, 
the C-terminal deletion mutants were still able to complement the MMC hypersensitivity of FA-
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F cells. The ability of the FANCFdelC31 mutant to complement FA-F cells was not a result of 
overexpression of this protein, since low expression levels of this mutant protein by a leaky 
inducible vector (pMEP4) or by stable integration (pIRES neo) still corrected the MMC 
hypersensitivity (de Winter, unpublished data). Since the mutant FANCFdelC31 also corrects 
the MMC hypersensitivity of patient cell line EUFA1228, (J.P. de Winter, unpublished data) the 
complementing activity of this mutant is also not cell line-dependent. We infer from our results 
that the FANCFdelC31 mutant protein has a reduced affinity for the other members of the 
complex, undetectable by co-immunoprecipitation experiments because of the stringent 
conditions of this assay, but sufficient for a functional FA pathway. This conclusion is 
supported by our data showing an interaction between the FANCFdelC31 mutant and the 
FANCC/FANCE subcomplex in the mammalian three-hybrid assay, which was undetectable in 
co-immunoprecipitation experiments.  
 
The first 15 amino acids of FANCF are predicted to form an a-helix sharing 60% homology 
with Xenopus FANCF. This region is essential for the function of FANCF, since a FANCF 
mutant in which these amino acids were deleted failed to correct the MMC hypersensitivity of 
EUFA698 cells. This FANCF mutant appeared to have a normal nuclear localization and a 
reduced interaction with FANCA and FANCG, indicating that this particular region in FANCF 
is not directly involved in the nuclear targeting of FANCF, but crucial for the stable binding to 
FANCA and FANCG. Interestingly, the FANCF mutant 1-15del failed to co-precipitate with 
FANCC and FANCE, suggesting that this particular N-terminal region in FANCF is required 
for the presence of FANCC and FANCE within the FA core complex. The mammalian three-
hybrid system confirms this finding and provides strong evidence for direct interaction between 
the first 15 amino acids of FANCF and the FANCC/FANCE subcomplex.  
 
To identify functionally relevant residues in the N-terminus of FANCF, we generated several 
mutations in the first 48 amino acids that contain two predicted a-helices. Surprisingly, we 
could not obtain inactive or partially functional mutants without the additional removal of the 
last 31 amino acids when we assayed for the ability to complement the MMC hypersensitive 
phenotype of FA-F cells. This implies that the FANCA-FANCG interaction needs to be 
disturbed before amino acid substitutions in the N-terminus of FANCF show an effect in this 
assay. However, when tested in the M3H assay, mutations in the N-terminus of FANCF were 
sufficient to interfere with the binding of the FANCC/FANCE subcomplex. Apparently, the 
binding of FANCA and FANCG to the C-terminus of FANCF stabilizes the interaction of 
factors that bind to the N-terminus of FANCF, in particular the FANCC/FANCE subcomplex. 
By removing the C-terminus of the FANCF protein we interfered with this stabilizing effect. In 
the mammalian three-hybrid assay we do not need to interfere with the binding of the 
FANCA/FANCG subcomplex, since in this assay FANCA and FANCG are not present. What 
we have essentially tested in the mammalian three-hybrid assay and the MMC test with the C-
terminally truncated N-terminal mutants is the same; the interaction with the FANCC/FANCE 
subcomplex in absence of the FANCA/FANCG subcomplex. Accordingly, the results are the 
same. The detection of a weak interaction between FANCA and FANCE (Ref. 16 and Fig. 6A) 
and between FANCA and FANCC (14) in co-immunoprecipitation experiments on lysates of 
FA-F cells indicates that these proteins have some affinity for each other, but that these 
interactions need to be stabilized by the presence of FANCF. The results of our experiments 
suggest that the binding of the FANCC/FANCE subcomplex to the N-terminus of FANCF (in 
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case of the C-terminal deletion mutants) or the binding of the FANCA/FANCG subcomplex to 
the C-terminus of FANCF (in case of the N-terminal missense mutants) is sufficient to activate 
the FA pathway. 
 
 From the non-functional mutants we identified four critical regions defined by a group of 
residues essential for the proper function of FANCF. One region consists of 3 consecutive 
negatively charged residues (Glu-2, Asp-9, Glu-13) located at one side of the first a-helix. It is 
tempting to speculate that this region interacts through salt bridges with the 3 positively charged 
residues (Arg-32, Arg-39, Arg-46) located at one side of the second a-helix to form a functional 
domain. Another important region involves 3 conserved hydrophobic amino acids on one side 
of the first a-helix (Leu-5, Leu-8, Leu-15), which appear to form a binding site for the 
FANCC/FANCE subcomplex. The conserved arginines (Arg-10 and Arg-47) and 
phenylalanines (Phe-11 and Phe-48) in the first and second a-helix form the third critical region 
in the N-terminus of FANCF. These 4 residues combined are involved in the association with 
the FANCC/FANCE subcomplex and may either be a part of the interaction domain or stabilize 
this domain. A fourth critical region in the FANCF protein is formed by a stretch of serine-
threonine residues in the loop region between the two a-helices. Although there is no evidence 
as yet for post-translational modification of FANCF, this specific region could be the target for 
phosphorylation by a serine/threonine kinase. Alternatively, these serines and threonines might 
be involved in DNA or protein binding through the formation of hydrogen bonds. Our data 
show that this particular region plays a role in the direct interaction with the FANCC/FANCE 
subcomplex. Finally, the FANCF region (amino acid residues 145-209) homologous to the 
prokaryotic RNA binding protein ROM does not seem to have an essential ROM-like function. 
The FANCF mutants R172A, E172P and R173A (equivalent in ROM to amino acids Q24 and 
R25, respectively) did not affect the function of FANCF.  
 
We realize that these mutagenesis studies need to be interpreted with caution, because of the 
risk to affect the general structure of the protein. However, since amino acid changes in the N-
terminus and even deletions of the C-terminus of FANCF were tolerated, the FANCF structure 
seems to be very stable and flexible. Also the fact that a deletion of the C-terminus only 
inactivates a subset of the N-terminal FANCF mutants indicates that it is very difficult to affect 
the structure of the FANCF protein. Consistent with this idea is that none of the identified FA-F 
patients have missense mutations in FANCF, but rather have nonsense mutations or deletions 
(5). Furthermore, an in vitro revertant of EUFA698 cells expresses a mutant FANCF protein 
that lacks amino acids 76 to 84, which is still functional. The only mutation that might have 
changed the structure of the FANCF protein is the N-terminal deletion mutant, since this is the 
only single mutant that is unable to restore the MMC hypersensitivity of the FA-F cells.  
 
Our results suggest a sequential recruitment of the FA gene products in which the FANCF 
protein has a key role in linking different subcomplexes (FANCA/FANCG and 
FANCC/FANCE) and possibly other components together. Therefore, we propose that FANCF 
acts as an adaptor protein that plays a key role in the proper assembly of the FA core complex. 
We infer from our and published data that FANCF stabilizes the interaction between the 
FANCC/FANCE subcomplex and the FANCA/FANCG subcomplex and locks the whole FA 
core complex in a conformation that is essential to perform its function. 
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It is generally accepted that the FA proteins interact with each other to form a multiprotein 
nuclear complex that functions in a common cellular pathway. This pathway is activated during 
the S phase of the cell cycle and is required for the response to stalled replication forks 
(Kennedy & D’Andrea, 2005). In this Chapter, I will first present the molecular architecture of 
the FA pathway through a model that describes the sequential assembly and subcellular 
localization of the FA proteins. The proposed model is based on co-immunoprecipitation and 
two-/three-hybrid experiments as well as on results presented in this thesis. Secondly, I will 
describe a model for the function of the FA pathway in the repair of interstrand DNA cross-
links (ICLs).  
 
 
 
 
MOLECULAR ARCHITECTURE OF THE FA PATHWAY 
 
To facilitate the description of the molecular architecture of the FA pathway, FA proteins are 
categorized according to their role in the monoubiquitination of FANCD2. Most of the FA 
proteins are required for this monoubiquitination step and are referred to as the upstream part of 
the pathway. However, FANCD1/BRCA2 and FANCJ/BRIP1 are not required for this event 
and are therefore positioned downstream of FANCD2 (Figure 1). 
 
 
 
1. FA protein-protein interactions upstream of FANCD2 and the formation of the FA core 
complex 
 
Eight of the FA proteins (FANCA, B, C, E, F, G, L and M) and one FANCA-associated protein, 
FAAP100, assemble in an ordered sequence of events to form a nuclear ubiquitin ligase, “the 
FA core complex” (see Figure 1). This multisubunit complex is essential for the 
monoubiquitination of FANCD2. The FANCI protein, which has not been identified yet, seems 
to have a different role, since in the absence of FANCI, the FA core complex is properly formed 
but FANCD2 is not monoubiquitinated (Levitus et al., 2004). Therefore, FANCI is probably not 
a member of this FA core complex but may assist the complex in the monoubiquitination of 
FANCD2. In this respect, the FANCI protein is also considered to function upstream of 
FANCD2. At the initial stages of the sequential assembly of the FA core complex, specific 
interactions between FA proteins take place in the cytoplasm to form two FA subcomplexes 
(FANCA/FANCG and FANCB/FANCL/FAAP100). These subcomplexes might enter the 
nucleus through the nuclear pores via active transport, since their cumulative molecular size 
exceeds the limit of 60 kDa for passive transport through the nuclear pore. The transport of 
these subcomplexes probably takes place by recognition of nuclear localization signal (NLS) 
sequences within the FANCA and FANCB proteins. The nucleocytoplasmic shuttling of several 
FA proteins appears to be regulated in a cell cycle-dependent manner (Thomashevski et al., 
2004; Mi & Kupfer, 2005). 
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A physical association between FANCA and FANCG is believed to represent an early step in 
the assembly of the FA core complex, since their interaction is observed in all non A/G FA 
complementation groups (Waisfisz et al., 1999a; de Winter et al., 2000b). The direct interaction 
between these two proteins appears to be mediated by the N-terminus of FANCA (amino acids 
1 to 40 including the NLS motif) and the tetratricopeptide repeat (TPR) motifs 5 and 6 at the C-
terminus of FANCG (Kruyt et al., 1999; Garcia-Higuera et al., 1999, 2000; Kuang et al., 2000; 
Gordon & Buchwald, 2003; Blom et al., 2004, Hussain et al., 2006). This association might 
regulate the nuclear accumulation of FANCA, as the NLS is probably shielded after binding 
FANCG. In addition to the N-terminal region, the nuclear accumulation of FANCA also 
requires its C-terminal portion (Lighfoot et al., 1999). This region does not contain a NLS 
sequence and is not able to translocate a GFP fusion protein to the nucleus. Therefore, the C-
terminus might be needed to replace FANCG from the N-terminal NLS sequence, perhaps by 
phosphorylation of FANCA at a site adjacent to its NLS (Yamashita et al., 1998; Yagasaki et 
al., 2001; Harreman et al., 2004).  
The FANCG protein contains several TPR motifs, which function as scaffolds for protein-
protein interactions (Blom et al., 2004). This suggests that FANCG plays an important role in 
the assembly and stability of the multiprotein FA core complex. Indeed, FANCG is able to 
mediate the interaction between FANCA and the C-terminus of FANCF (Medhurst et al., 2001; 
Gordon & Buchwald, 2003; Chapter 5). However, studies on the FANCG-FANCF interaction 
were unable to delineate the FANCG binding region, perhaps because the fragments of FANCG 
used in these studies disrupted the superhelical structure of the TPR domains required for 
binding FANCF (Medhurst et al., 2001; Gordon & Buchwald, 2003; Blom et al., 2004; Hussain 
et al., 2006). Furthermore, the C-terminal region of FANCG is important for recruitment of 
FANCC in the nuclear FA core complex (Kuang et al., 2000; Nakanishi et al., 2001), probably 
through its direct interaction with FANCF (see below). FANCG also appears to stabilize the 
interaction between FANCA and FANCL (Medhurst et al., 2006) and additional roles have 
been proposed for FANCG as it seems to have other direct binding partners such as 
FANCD1/BRCA2 and the RAD51 paralog XRCC3 (Hussain et al., 2003, 2006). 
 
The FANCB, FANCL and FAAP100 proteins form a ternary complex (Medhurst et al., 
unpublished data) and the FANCB/FANCL complex directly binds to FANCA (Medhurst et al., 
2006). The stability and the nuclear localization of this group of proteins seem to depend on 
each other, as well as on the nuclear FANCM protein. Recent studies showed that the nuclear 
accumulation of FANCL depends on FANCA FANCB and FANCM (Meetei et al., 2003b, 
Medhurst et al., 2006). Similarly, the nuclear accumulation of FANCA depends on FANCB, 
FANCM and, to a lesser extent, on FANCL (de Winter et al., 2000b; Meetei et al., 2005; 
Medhurst et al., 2006).  The FANCA/FANCG dimer and the FANCB/FANCL/FAAP100 
ternary complex probably enter the nucleus independently, since the interaction between 
FANCA and FANCL is only found in the nuclear compartment and FANCA mutants that are 
affected in their nuclear accumulation are unable to interact with FANCL (Medhurst et al., 
2006). In the nucleus, it is likely that these two subcomplexes physically assemble around 
FANCM, as no interaction between FANCA, FANCG and FANCL is found in the absence of 
FANCM (Medhurst et al., 2006). The association of these subcomplexes with FANCM appears 
to occur in a succession of events, in which the FANCA/FANCG dimer first binds FANCM 
followed by the FANCB/FANCL/FAAP100 subcomplex. This is supported by the observation 
that in absence of FANCM, the expression levels of FANCA and FANCG are much more 
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affected than the levels of FANCL (Meetei et al., 2005).  Furthermore, since the nuclear 
accumulation of FANCA is also regulated by FANCB and FANCL, it is likely that the 
association of the FANCB/FANCL subcomplex with FANCA masks the nuclear exports signals 
present in FANCA and maintains FANCA in the nucleus (Ferrer et al., 2005). The FANCL 
protein, which contains WD40 domains, also might play an important role in the assembly and 
stability of these subcomplexes, since such domains are known to mediate protein-protein 
interactions (Meetei et al., 2003b; Gurtan et al., 2006). 
 
The other FA protein that partially resides in the cytoplasmic compartment of the cell is 
FANCC. The expression of FANCC is regulated during the cell cycle and seems to be subjected 
to proteasome-dependent proteolysis (Heinrich et al., 2000). Therefore, the nuclear transport of 
FANCC is also cell cycle-dependent and might be initiated at the same time as the 
FANCA/FANCG and FANCB/FANCL/FAAP100 subcomplexes. However, little is known 
about how FANCC is imported into the nucleus. One possibility is that FANCC enters the 
nucleus through passive transport as its molecular size is about 60 kDa, or via an unidentified 
nuclear localization signal (NLS) within its sequence. Alternatively, the nuclear import of 
FANCC occurs via its binding to a NLS-cargo protein. This protein could be FANCE, which 
contains two NLS motifs and binds directly to FANCC (Chapters 2, 4 & 5; Medhurst et al., 
2001; Pace et al., 2002; Taniguchi & D’Andrea, 2002; Godon & Buchwald, 2003, 2005). Our 
localization study reveals that the nuclear accumulation of FANCE is not exclusively dependent 
on its NLS motifs, but also relies on FANCC (Chapter 4). We found that the FANCC and 
FANCE proteins have a mutual interdependence in the FA pathway. In absence of FANCC, the 
expression level of nuclear FANCE is disturbed, and similarly, in absence of FANCE, FANCC 
is not able to accumulate in the nucleus (see also Pace et al., 2002; Taniguchi & D’Andrea, 
2002). Furthermore, FANCC deletion and missense mutants are defective in FANCE binding 
and are incapable to accumulate in the nucleus (Pace et al., 2002; Gordon & Buchwald, 2003). 
Therefore, FANCC and FANCE affect each other in their nuclear accumulation and/or stability.  
 
We have demonstrated that the FANCC/FANCE subcomplex is able to bind directly to the 
FANCF protein (Chapter 5). FANCF is a small nuclear protein that was first thought to be a 
RNA binding protein based upon homology to the prokaryotic ROM protein (de Winter et al., 
2000a). However, site-directed mutagenesis of the FANCF region homologous to ROM reveals 
that FANCF has a different function (Chapter 5). Results from two-hybrid studies show that 
neither FANCC nor FANCE binds to FANCF (Chapter 5). However, three-hybrid studies 
indicate that FANCC allows direct interaction between FANCF-FANCE (Chapter 5) and, 
similarly, FANCE mediates the interaction between FANCF-FANCC (Gordon et al., 2005). 
Therefore, a ternary complex exists between FANCC, FANCE and FANCF. We found that the 
first 15 amino acids of FANCF are necessary to bind and recruit the FANCC and FANCE 
proteins, which suggests that the N-terminus of FANCF binds both proteins simultaneously. It 
has been shown that the interaction between FANCA and FANCL depends on FANCB, 
FANCG and FANCM, but is independent of FANCC, FANCE and FANCF (Medhurst et al., 
2006). Therefore, the formation of the FANCC/FANCE/FANCF subcomplex seems to 
represent a downstream event in the assembly of the FA core complex. The FANCA, FANCC, 
FANCE and FANCG proteins seem to have some affinity for each other but they require 
FANCF to stabilize their interaction. In the assembly of the FA core complex, FANCF plays a 
crucial role since it allows the formation of a larger and stable complex by bridging the FANCG 
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protein, which is connected to the FANCM/FANCA/FANCB/FANCL/ FAAP100 subcomplex, 
and the FANCC/FANCE subcomplex.  
The FANCC/FANCE subcomplex links to another FA protein, FANCD2, the key substrate 
for the ubiquitin ligase of the FA core complex (Chapter 4; Pace et al., 2002; Gordon & 
Buchwald, 2003; Gordon et al., 2005). In fact, FANCE binds both FANCC and FANCD2 but 
the FANCC and FANCD2 proteins do not directly interact with each other. Therefore, the 
ternary complex formation between these proteins seems to be mediated by FANCE (Gordon et 
al., 2005). Along this line, our study suggests that different regions of FANCE interact with 
FANCC and FANCD2 (Chapter 4). The N-terminus of FANCD2 binds FANCE toward a C-
terminal region, while full-length FANCC binds to a minimal internal portion of FANCE 
(amino acids 150-311) encompassing its NLS motifs (Chapter 4; Gordon & Buchwald, 2003; 
Gordon et al., 2005). Consequently, the FANCC/FANCE subcomplex physically connects the 
FANCD2 protein to the FA core complex (see Figure 1). Interestingly, the N-terminal region of 
FANCD2 is also involved in binding FANCD1/BRCA2 (Gordon & Buchwald, 2003; Hussain 
et al., 2004). This overlapping region of protein-protein interactions in FANCD2 may be of 
functional importance (see below). In summary, the FANCC/FANCE subcomplex interacts 
with FANCF and FANCD2. However, it is still unclear whether this subcomplex mediates at 
the same time the interaction with FANCF and FANCD2, or whether it forms a trimeric 
complex with each protein independently. This issue can be clarified by performing a four-
hybrid study of these proteins. 
 
 
 
Monoubiquitination of FANCD2 
 
Following the proper assembly and stability of the FA core complex, FANCL, through its 
RING domain, might allow the recruitment of an E2 ubiquitin-conjugating enzyme (Gurtan et 
al., 2006). This enzyme could be FANCI, which is involved in the monoubiquitination of 
FANCD2 (Levitus et al., 2004), but could also be an as yet unidentified E2 enzyme. There is no 
direct association between FANCL and its substrate FANCD2, but this interaction seems to be 
mediated by FANCE in collaboration with the rest of the FA core complex. The results reported 
in Chapter 4 suggest that FANCI is implicated in the nuclear retention of FANCC, FANCE and 
FANCD2. Therefore, it is possible that the interaction of the FANCC/FANCE/FANCD2 ternary 
complex with FANCI subsequently leads to the FANCL mediated transfer of the ubiquitin 
moiety to FANCD2. 
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Figure 1. Model for the sequential assembly of the FA proteins. In the cytoplasm, FANCA and FANCG 
from a dimer and FANCB, FANCL and FAAP100 a ternary complex. The FANCA/FANCG and 
FANCB/FANCL/FAAP100 subcomplexes translocate to the nucleus independently, where they associate 
with FANCM. FANCA, FANCG and FANCL are thought to mediate the interaction with FANCM. FANCC 
enters the nucleus, passively or via a carrier protein, where its binds to FANCE and forms the 
FANCC/FANCE subcomplex. The N-terminus of FANCF binds the FANCC/FANCE subcomplex and the 
C-terminus of FANCF binds FANCG, allowing stability and proper formation of the whole FA core 
complex. FANCD2 is physically linked to this large complex by binding the FANCC/FANCE subcomplex. 
The E3 ubiquitin ligase FANCL, probably with the help of FANCI, activates FANCD2 by 
monoubiquitination on Lys 561. Following monoubiquitination, FANCD2 localizes to chromatin where it 
colocalizes with D1/BRCA2, RAD51 and BRCA1 in nuclear foci. These nuclear foci are thought to represent 
the sites of DNA damage, when a replication fork gets stalled on a DNA cross-link. Monoubiquitinated 
FANCD2 and FANCE seem to promote the chromatin loading of D1/BRCA2 at sites of DNA damage. The 
FANCG binding might be important to stabilize D1/BRCA2 onto the chromatin. In turn, D1/BRCA2 can 
load the homologous recombination protein, RAD51, onto single-strand DNA. The 5’® 3’ DNA helicase 
FANCJ/BRIP1 colocalizes also to these nuclear foci, along with BRCA1. This latter protein also interacts 
with FANCA. Monoubiquitinated FANCD2 is de-activated by UPS1. The action of the FA proteins is 
thought to participate in the resolution of stalled replication forks at site of DNA interstrand cross-link. 
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2. FA protein-protein interactions downstream of FANCD2 
 
Following monoubiquitination, FANCD2 is targeted to chromatin and colocalizes in nuclear 
foci with numerous proteins involved in DNA processing, such as FANCD1/BRCA2, 
FANCJ/BRIP1, BRCA1, RAD51 and PCNA (see also Figure 2) (Garcia-Higuera et al., 2001; 
Cantor et al., 2001; Taniguchi et al., 2002b; Wang et al., 2004; Howlett et al., 2005). These 
nuclear foci seem to represent the sites of DNA damage where the replication fork stalls at a 
DNA cross-link. The FA core complex proteins also have the ability to associate with 
chromatin and play a crucial role in chromatin targeting of monoubiquitinated FANCD2 
(Matsushita et al., 2005; Mi & Kupfer et al., 2005). Furthermore, efficient DNA damage-
induced monoubiquitination and nuclear foci formation of FANCD2 requires the ATR (ATM-
and Rad3-related) protein kinase signal transducer as well as the single-strand DNA binding 
protein RPA (Andreassen et al., 2004). 
 
The FANCD1/BRCA2 protein is directly implicated in the repair of DNA double-strand 
breaks (DSB) by homologous recombination (HR). This type of repair uses homology between 
two DNA strands to restore the original sequence of the broken DNA using one of the strands 
as a repair template (see Figure 2). In this HR repair process, D1/BRCA2 appears to regulate 
the RAD51 filament loading and extension onto the single-strand DNA (ssDNA) at sites of 
damage (for reviews, West, 2003; Shivji & Venkitaraman, 2004). The interaction model 
between D1/BRCA2 and RAD51 suggests that the internal BRC repeat region in D1/BRCA2 
provides a structure for the assembly of multiple RAD51 monomers and that the binding of its 
C-terminal oligosaccharide or oligonucleotide binding (OB) folds to ssDNA provides a way to 
dislodge RPA from ssDNA, enabling the formation of the RAD51 filament on that ssDNA 
(Powell & Kachnic, 2003; Shin et al., 2003). Subsequently, RAD51 can catalyze the pairing and 
the exchange of ssDNA with an intact DNA template (either the sister chromatid or the 
homologous chromosome). Interestingly, although controversial (see also Digweed et al., 
2002), normal RAD51 foci formation is observed in patient-derived cell lines from all FA 
complementation groups, except for the FA-D1 group (Godthelp et al., 2002, 2006; Litman et 
al., 2005). Since cells from the FA-J and FA-D1 patient groups show the monoubiquitinated 
form of FANCD2, this defective RAD51 process provides a test to distinguish between these 
two groups.    
 
The D1/BRCA2 protein interacts directly with both FANCD2 and FANCG, and co-
immunoprecipitates with FANCE (Hussain et al., 2003, 2004; Wang et al., 2004). Two-hybrid 
analysis revealed that the FANCG protein binds the N-terminal as well as the C-terminal parts 
of D1/BRCA2, around the BRC repeats and colocalizes in nuclear foci with both D1/BRCA2 
and RAD51 (Hussain et al., 2003). As mentioned earlier, FANCE and the C-terminus of 
D1/BRCA2 share the same N-terminal binding site of FANCD2 (Gordon & Buchwald, 2003; 
Hussain et al., 2004). The functional role of these D1/BRCA2 protein-protein interactions 
remains unclear. However, there is evidence that monoubiquitinated FANCD2 present in 
chromatin is involved in the chromatin loading of D1/BRCA2 (Wang et al., 2004). In addition, 
the interaction between FANCE and D1/BRCA2 appears to be independent of FANCD2 (Wang 
et al., 2004). Therefore, it is tempting to speculate that FANCE recruits monoubiquitinated 
FANCD2 to D1/BRCA2 and facilitates their targeting onto damaged chromatin. This process 
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might be followed by stabilization of the D1/BRCA2-RAD51 complex on ssDNA by FANCG, 
throughout its binding on both ends of D1/BRCA2 (Hussain et al., 2003, 2006). 
 
In the same DNA damage-induced nuclear foci, the DNA 5’® 3’ helicase FANCJ/BRIP1 
binds to the C-terminal BRCT repeats of BRCA1 (Cantor et al., 2001). BRCA1 is also involved 
in homologous recombination repair and appears to regulate the 3’® 5’exonuclease activity of 
the RAD50/MRE11/NBS1 (RMN) complex (Moynahan et al., 1999; Wu et al., 2000). FANCJ 
is not the only FA protein linked to BRCA1. Indeed, BRCA1 interacts physically with FANCA 
and associates with D1/BRCA2 (Chen et al., 1998; Folias et al., 2002). BRCA1 is important for 
the translocation/accumulation of monoubiquitinated FANCD2 at sites of DNA damage 
(Garcia-Higuera et al., 2001; Vandenberg et al., 2003). A recent model for the function of 
FANCJ and BRCA1 in the homologous recombination process proposed that FANCJ functions 
downstream of the RAD51 loading by D1/BRCA2 and that its activity is controlled by BRCA1 
(Cantor & Andreassen, 2006). Thus, under the control of BRCA1, FANCJ prevents the release 
of the RAD51 filament from ssDNA until homologous recombination has been completed. It 
will be crucial to delineate the protein-protein interactions of FANCJ within the FA pathway. 
The BRCA1 and FANCA proteins have also a common direct binding partner, the BRG1 
(brm-related gene 1) protein, which is a subunit of the SWI/SNF chromatin-remodeling 
complex (Bochar et al., 2000; Otsuki et al., 2001). FANCA might therefore be involved in the 
initial phase of the ICL repair by sensing the lesion or the aberrant chromatin structure around 
the ICL lesion. FANCA might also be used as a docking point at DNA damage site for the 
assembly of BRCA1 and its associated proteins, such as FANCJ.  
Finally, in the late S phase of the cell cycle, the monoubiquitinated FANCD2 is deactivated 
by the deubiquitinating enzyme USP1, thereby inactivating the FA pathway (Nijman et al., 
2005). At mitosis, the FA core complex is released from chromatin (Mi & Kupfer, 2005).  
  
 
 
 
FUNCTION OF THE FA PATHWAY IN  
DNA INTERSTRAND CROSS-LINK REPAIR 
 
 
Accumulating evidence suggests that the FA pathway is activated by DNA interstrand cross-
link (ICL) damage. In addition, the FA pathway seems directly involved in the handling of ICL 
together with proteins from several DNA repair pathways. These processes occur during the S 
phase of the cell cycle, when DNA is duplicated by DNA polymerases at multiple replication 
forks (for reviews, see Kennedy & D’Andrea, 2005; Niedernhofer et al., 2005). The key 
features on how the FA pathway cooperates with the nucleotide excision (NER), translesion 
synthesis (TLS) and homologous recombination (HR) repair pathways to restore the ICL 
damage are outlined in Figure 2.  
 
The ICL lesion covalently links the two complementary strands of DNA and prevents their 
separation, thereby obstructing the replication (or transcription) process (Figure 2, step 1). This 
replication block probably triggers the signaling to specific proteins, such as ATR (step 2). The 
activation of ATR represents an early response caused by the replicative stress, which results in 
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the phosphorylation of many substrates, including FANCD2 (Andreassen et al., 2004; Pichierri 
& Rosselli, 2004). ATR also promotes the monoubiquitination of FANCD2, possibly through 
the activation of FANCM. The DNA helicase/translocase FANCM has several ATR 
phosphorylation sites that could be phosphorylated and might initiate the FA core complex 
formation (Meetei et al., 2005). Monoubiquitinated FANCD2 seems important for the 
recruitment of D1/BRCA2 and RAD51 to chromatin (Wang et al., 2004), and colocalizes within 
nuclear foci where numerous DNA repair proteins, such as the ssDNA binding protein RPA and 
the proliferating cell nuclear antigen (PCNA) protein, are concentrated (Howlett et al., 2005).  
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To separate the two cross-linked DNA strands, the ICL lesion must first be released from one 
of the two damaged strands. For this unhooking step, a cleavage occurs on one of the damaged 
DNA strands upstream of the lesion by an unidentified endonuclease (Niedernhofer et al., 2004; 
Dendouga et al., 2005). Through this endonucleolytic cleavage the stalled replication fork is 
converted to a double-strand break (DSB) (step 3). It has been proposed that the FA pathway is 
important for the stabilization of the stalled replication fork after DSBs are formed (Rothfuss & 
Grompe, 2004) and possibly prevents the DSB from being processed by the non-homologous 
end joining pathway. The presence of the putative helicase FANCM in the vicinity of the DNA 
damage might facilitate the second incision by unwinding the DNA helix around the ICL lesion 
(step 4). This second incision must occur on the same strand but on the other side of the lesion 
(step 5). In this case, the likely endonuclease is the heterodimer ERCC1-XPF complex, which is 
also essential for the NER pathway (Niedernhofer et al., 2004). It seems that the formation of a 
DSB creates a substrate for ERCC1-XPF by revealing a 3’ DNA end near the ICL. In addition, 
ERCC1-XPF is guided by the presence of ssDNA binding protein RPA around the ICL lesion. 
This second incision releases the ICL from one DNA strand and creates a gap that can be filled 
by the error-prone translesion polymerases (steps 6 and 7). These TLS polymerases are likely to 
incorporate a mutation in the nucleotide sequence at the site opposing the cross-linked base of 
the newly synthesized DNA (Zheng et al., 2003). This feature is also consistent with the 
characteristic hypomutability of FA cells at the hprt locus (Papadopoulo et al., 1990). The 
residual ICL damage on the second strand is subsequently excised by the NER system or 
eliminated by spontaneous hydrolysis (step 8).  
 
 
 
 
Figure 2 (see opposite page). Model for the function of the FA pathway in repair of DNA ICL. 1) 
Presence of a DNA ICL lesion. 2) During the S phase of the cycle cell, the DNA replication process by 
DNA polymerase is interrupted at the ICL lesion. In response to the stalled replication fork, the ATR 
kinase is recruited and activated. Subsequently, ATR phosphorylates multiple proteins, including 
FANCD2 (see central box). Phosphorylated FANCD2 is monoubiquitinated by the catalytic subunit of the 
FA core complex, FANCL. The activated FANCD2 colocalizes in nuclear foci at the site of replication 
stress with numerous proteins involved in HR and TLS. 3) In the process of repair, a first incision by an 
unknown endonuclease (scissor) occurs in one of the template strands upstream of the ICL lesion, which 
generates a DSB intermediate and ssDNA end. 4) A second incision is required to separate the two 
template strands. Local unwinding of the double helix around the ICL by a DNA helicase, such as 
FANCM, might facilitate this step. 5) The second incision by the ERCC1-XPF endonuclease, on the other 
side of the ICL at the same strand, releases the lesion on one of the two strands. In addition, the binding of 
RPA at the ssDNA end is required for accurate cutting of ERCC1-XPF. 6) Release of the ICL on one 
strand creates a gap and the 3’ end that can be use to prime DNA synthesis. 7) The gap can be filled by 
TLS, which bypasses the damaged site on the complementary strand. 8) The TLS DNA polymerases 
produce point mutation at site of damage. 9) After that excision repair of the damaged site on the 
complementary strand and the integrity of the template strand is restored by normal DNA synthesis, or 
alternatively, that the unhooked ICL is removed by spontaneous hydrolysis, the DSB can be repaired by 
HR. This process is initiated by the resection of the broken end to reveal a 3’ single-strand overhang, 
which can invade and pair with its sister chromatid to form a joint molecule. 10-11) Several proteins are 
implicated in the HR repair process, such as RAD51, BRCA1, D1/BRCA2, PCNA and RPA. The FANCJ 
helicase might be required to unwind the forked duplex structure at this step. 12) Resolution of 
recombination intermediate, which probably involves the BLM-TOPOIIIa complex, restarts the DNA 
replication fork, where sister chromatid exchange (SCE) might occur or not. The FA pathway is turning 
off through the deubiquitination of FANCD2 by USP1. (Figure reprinted from Cell, Vol. 123 
(Niedernhofer et al.) Fanconi Anemia (Cross)linked to DNA repair, 1191-98. Copyright 2005, with 
permission from Elsevier).         
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The repair of the DSB proceeds by homologous recombination (steps 10 and 11), which is 
initiated by the resection of the broken end to reveal a 3’ end single-strand overhang (step 9). 
Loading of D1/BRCA2 onto damaged chromatin might allow the formation of the RAD51 
filament on the 3’ single-strand overhang, which is able to invade the DNA template and pair 
with its sister chromatid to form a joint molecule (e.g. Holliday junction). The FANCJ 5’® 3’ 
DNA helicase might help in this process by opening the homologous recombination 
intermediate D-loop structure (Gupta et al., 2005). At the appropriate time, FANCJ might be 
activated by BRCA1 to release the RAD51 filament from the invading strand of the D-loop 
(Cantor & Andreassen, 2006). Although FANCD2 is able to bind DNA ends and Holliday 
junction, it remains unclear how FANCD2 processes these structures (Park et al., 2005). The 
resolution of Holliday junction recombination intermediates by the BLM helicase-
Topoisomerase IIIa (BLM-TOPOIIIa) complex, which is associated with the FA core complex, 
enables expansion of the heteroduplex and re-establishment of the replication fork, where DNA 
polymerases can process (step 12) (Meetei et al., 2003a; Wu et al., 2005). The resolution of the 
Holliday junction may probably not result in a sister chromatid exchange (SCE) since the BLM 
helicase suppresses crossing over via the TOPOIIIa (Wu & Hickson, 2003). In the late S phase 
of the cell cycle, the FA pathway is inactivated by the USP1 mediated deubiquitination of 
FANCD2 (Nijman et al., 2005). 
 
This model is supported by studies on human and mouse FA cells as well as on mutant 
chicken DT40 cells, which reveal that the error-prone translesion polymerases and the 
homologous recombination repair act in the FA pathway (Yamamoto et al., 2003; Hirano et al., 
2004; Niedzwiedz et al., 2004; Yang et al., 2005). However, the exact function of FANCD2 in 
mediating homologous recombination repair remains unknown. FANCD2 might function in a 
sub-homologous recombination repair pathway independent of BRCA2 and RAD51, or it might 
be also involved in later steps of HR, after RAD51 foci formation (Nakanishi et al., 2005; 
Ohashi et al., 2005; Yamamoto et al., 2005). Further studies are required to resolve this central 
issue in FA research. 
 
Despite the identification of eleven FA proteins the function of the FA pathway in ICL repair 
remains incomplete and the discovery of other components of the FA pathway should improve 
our understanding of this complex chromosomal instability syndrome. Furthermore, the 
crystallographic structure of the FA core complex appears a valuable tool to understand how 
this complex assembles. 
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Summary 
 
 
Fanconi anemia (FA) is a rare recessive chromosomal instability syndrome with both autosomal 
and X-linked inheritance. Individuals affected with FA display diverse clinical symptoms, 
which make it difficult to diagnose patients based on phenotypical aspects. Rather, accurate 
diagnosis is based on cellular aspect, as the cells of FA patients are extremely sensitive to DNA 
interstrand cross-linking agents. FA is often apparent at birth and presents with particular 
congenital anomalies that include short stature (growth retardation), defects in thumbs or 
forearms and skin abnormalities (café-au-lait spots). Most of the FA patients develop 
pancytopenia due to bone marrow failure (at the median age of 7 years) and acute myeloid 
leukemia. In addition, the patients that survive to adulthood have early onset of solid tumors, 
principally squamous cell carcinoma of the head and neck and anogenital region. 
 
The genetic heterogeneity in FA was traditionally established using cell fusion experiments 
that complement the MMC sensitivity of the FA cells. This approach allowed the identification 
of several complementation groups and each group represents FA patients carrying mutations in 
the same gene. The multiple FA gene products interact in a common pathway, the “FA 
pathway”, which is involved in a complex network that maintains genetic stability. A defect of 
only one FA protein disrupts this pathway and thereby leads to the clinical and cellular 
phenotypes observed in FA patients.  
 
In Chapter 2, we have identified the gene that causes FA in the complementation group E 
patients, FANCE. This gene was isolated by functional complementation of a FA-E cell line 
(EUFA410) with a cDNA expression library that was also successfully used for the 
identification of FANCA, FANCC, FANCF and FANCG. The primary amino acid sequence of 
FANCE reveals that the encoded product is a novel protein with unknown function (like the 
other FA genes mentioned above). However, FANCE possesses two nuclear localization signals 
(NLS), which suggest that FANCE is a nuclear protein. The FANCE gene was mapped to 
chromosome 6p21.31 between microsatellite markers D6S439 and D6S1645, using radiation 
hybrid panels. The map location of FANCE, in the region amongst the HLA class 1 genes of the 
major histocompability complex, implies that the FA-E patients are unlikely to have unaffected 
HLA-matched sibling donor for successful bone marrow transplantation. Consequently, the 
cloning of FANCE makes the FA-E patients prime candidates for gene therapy trials. 
 
In Chapter 3, we describe a novel FANCE missense mutation (R371W) in two FA patients. 
We also present the mutations spectrum of the 7 FA-E patients identified so far worldwide.   
 
In Chapter 4, we investigated the nuclear localization of the FANCE protein. We found that 
the nuclear accumulation of FANCE is not entirely governed by its NLS motifs, but also 
depends on the FANCC protein. Furthermore, we studied the binding sites of FANCE with its 
direct binding partners: FANCC and FANCD2. Our data suggest that FANCE has different 
interaction domains for FANCC and FANCD2. 
 
In Chapter 5, we analyzed the role of FANCF in the FA core complex assembly and 
determined functionally important domains through an extensive site-directed mutagenesis 
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study. To predict important residues and domains in FANCF, we used a Xenopus laevis FANCF 
homolog. The study shows that the structure of FANCF is very stable and flexible and that 
FANCF acts as an adaptor protein, which functionally links the various FA proteins, and 
possibly other components. 
 
In conclusion, the research presented in this thesis has improved our understanding of the 
role of FANCE and FANCF within the FA core complex. The physical association of FANCF 
with numerous FA protein subcomplexes provides a new way to visualize the assembly of this 
large multi-protein nuclear complex. Additionally, the close association between FANCE and 
FANCC demonstrates the interdependence of the proteins inside the FA core complex.   
 
 
 
 
Samenvatting 
 
 
 
Het Fanconi anemie DNA onderhoudsmechanisme:  
focus op de FANCE en FANCF eiwitten 
 
 
 
Fanconi anemie (FA) is een zeldzaam, chromosomaal instabiliteitsyndroom, met zowel 
recessief autosomale als X-gebonden overerving. Personen met FA hebben een verscheidenheid 
aan klinische symptomen, wat het moeilijk maakt om een diagnose te stellen op grond van het 
fenotype van de patiënt. Een accurate diagnose is gebaseerd op cellulaire aspecten, omdat de 
cellen van FA patiënten extreem gevoelig zijn voor een bepaald type DNA beschadigende 
stoffen (DNA cross-linkers). FA is vaak zichtbaar bij de geboorte en presenteert zich met 
afwijkingen, zoals groeiachterstand, afwijkingen aan de duimen of onderarmen en 
huidafwijkingen (café-au-lait vlekken). De meeste FA patiënten ontwikkelen op jonge leeftijd 
pancytopenie, veroorzaakt door beenmergfalen en hebben een verhoogde kans op acute 
myeloide leukemie. Daarnaast hebben de patiënten die overleven tot aan de volwassenheid een 
grote kans op het ontwikkelen van solide tumoren, vooral plaveiselcel  carcinomen van het 
hoofd-hals gebied. 
 
FA is genetisch zeer heterogeen, met zeker 12 verschillende genen die, wanneer er een 
defect in optreedt, FA kunnen veroorzaken Deze genetische heterogeniteit werd traditioneel 
vastgesteld door middel van celfusie experimenten, waarbij de gevoeligheid voor DNA cross-
linkers verdwijnt wanneer de gefuseerde FA cellen een defect in verschillende genen hebben. 
Dankzij deze aanpak konden verschillende complementatiegroepen geïdentificeerd worden, 
waarbij elke complementatiegroep FA patiënten vertegenwoordigt die een mutatie hebben in 
hetzelfde gen. De FA genproducten werken samen in een biochemische proces, wat betrokken 
is in een complex netwerk dat genetische stabiliteit handhaaft. Een afwijking van één van de FA 
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genen, verstoort dit biochemische proces en veroorzaakt het klinische en cellulaire fenotype dat 
wordt waargenomen bij FA patiënten. 
 
In Hoofdstuk 2 hebben we het gen geïdentificeerd dat FA veroorzaakt in de patiënten die 
behoren tot complementatiegroep E, FANCE. Dit gen werd geïsoleerd door functionele 
complementatie van een FA-E cellijn (EUFA410), met een cDNA expressiebank die eveneens 
succesvol was gebruikt voor de identificatie van FANCA, FANCC, FANCF and FANCG. De 
aminozuursequentie van FANCE, onthult dat het een nieuw eiwit is met een onbekende functie 
(net zoals de andere hierboven genoemde eiwitten). Echter, FANCE heeft 2 nucleaire lokalisatie 
signalen (NLS), wat veronderstelt dat het FANCE eiwit zich in de celkern bevindt. FANCE ligt 
op chromosoom 6p21.31, tussen microsateliet markers D6S439 en D6S1645. Deze lokalisatie, 
in een regio met onder andere HLA klasse 1 genen van het major histocompatibiliteitscomplex, 
impliceert dat het onwaarschijnlijk is dat FA-E patiënten gezonde broers of zusters hebben met 
eenzelfde HLA typering voor een succesvolle beenmergtransplantatie. Derhalve maakt het 
identificeren van het FANCE gen FA-E patiënten goede kandidaten voor gentherapie. 
 
In Hoofdstuk 3, wordt een nieuwe pathogene aminozuur substitutie (R371W) in twee FA-E 
patiënten beschreven. Ook laten we het mutatiespectrum van de 7 tot nu toe geïdentificeerde 
FA-E patiënten wereldwijd zien. 
 
In hoofdstuk 4, is de nucleaire lokalisatie van het FANCE eiwit onderzocht. Er werd 
gevonden dat de nucleaire accumulatie van FANCE niet uitsluitend wordt geregeld door zijn 
NLS motieven, maar dat de nucleaire lokalisatie ook afhankelijk is van het FANCC eiwit. 
Verder zijn de bindingsplaatsen van FANCE met de directe binding partners FANCC en 
FANCD2 geanalyseerd. De data suggereren dat de bindingsplaatsen voor FANCC en FANCD2 
verschillend zijn. 
 
In hoofdstuk 5, is de rol van FANCF in de samenstelling van het nucleaire FA complex 
onderzocht en wordt geprobeerd delen van FANCF te vinden die essentieel zijn voor de functie 
van FANCF door middel van een uitgebreide mutatiestudie. Om belangrijke residuen en 
domeinen in FANCF aan te wijzen, hebben we een FANCF homoloog uit de klauwpad Xenopus 
laevis gebruikt. De studie liet zien dat de structuur van FANCF erg stabiel en flexibel is en dat 
FANCF zich gedraagt als een adaptor eiwit dat de verschillende FA eiwitten en mogelijk andere 
componenten aan elkaar koppelt. 
 
Samenvattend kunnen we concluderen dat het onderzoek, gepresenteerd in dit proefschrift, 
ons begrip over de rol die FANCE en FANCF spelen in de FA biochemische route spelen heeft 
vergroot. De interactie van FANCF met verschillende FA eiwitten, biedt nieuwe inzichten om 
de vorming van het nucleaire FA complex voor te stellen. Verder laat de nauwe samenwerking 
tussen FANCE en FANCC de onderlinge afhankelijkheid van de eiwitten in het complex zien. 
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List of abbreviations 
 
 
a.a  amino acid 
AML  acute myeloid leukemia 
AT  Ataxia telangiectasia  
ATM Ataxia telangiectasia 
mutated 
ATR  ATM and Rad3-related 
bp  base pair  
BRCA1   breast cancer gene 1              
BRCA2  breast cancer gene 2  
BRG1 brm (Drosophila 
brahma)-related gene  
BS  Bloom syndrome   
BMT  bone marrow transplant 
C-terminus carboxy-terminus 
CRM1 chromosome 
maintenance region 1 
DEB  diepoxybutane 
DNA  deoxyribonucleic acid 
DSB  double-strand break 
EGFP  enhanced green 
fluorescent protein 
EUFA European Fanconi 
anemia research group 
FA  Fanconi anemia 
GFP   green fluorescent protein 
HNPCC hereditary nonpolyposis 
colorectal cancer 
HR homologous 
recombination 
ICL  interstrand cross-link 
IR  ionizing radiation 
kDa  kilo Dalton 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MMC  mitomycin C 
MMR  mismatch repair  
MRE11  meiotic recombination 11 
MRN MRE11/RAD50/NBS1 
complex 
N-terminus amino-terminus 
NBS Nijmegen breakage 
syndrome 
NER nucleotide excision 
repair 
NES  nuclear export signal 
NLS nuclear localization 
signal 
OB oligosaccharide/ 
oligonucleotide binding 
folds 
RAD51  radiation gene 51 
RPA  replication protein A  
PCNA proliferative cell nuclear 
antigen 
SCE sister chromatid 
exchange 
SSA  single-strand annealing 
SCC  squamous cell carcinoma 
TCR transcription coupled 
repair 
TLS  translesion synthesis 
WS  Werner syndrome  
WT  wild-type 
XP  Xeroderma pigmentosum 
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